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Abstract 
Chronic allograft dysfunction (CAD) following kidney transplantation is characterized 
by progressive fibrosis and a smoldering inflammatory infiltrate. A modified Fischer 
344 (RT1lvl) to Lewis (RT1l) rat renal allograft model was used to study transcriptomic 
changes during the initiation and progression of CAD and to identify potential 
therapeutic modes of action of treatment with 13cRA previously shown to limit the 
development of CAD. Transcriptomic profiling was performed using Affymetrix DNA 
arrays at time points 0, 7, 14 and 56 days after transplantation. The animal model 
showed development of significant chronic fibrotic damage with accompanying 
inflammatory infiltrate by day 56 after transplantation. Regulatory pathways were 
identified by the Database for Annotation, Visualization, and Integrated Discovery 
(DAVID) and modulated, based on the Kyoto Encyclopedia of Genes and Genomes 
(KEGG) pathways database. 
Microarray analysis revealed dramatic changes in the mRNA expression levels of 
genes associated with inflammation and fibrosis, as well as the hedgehog and WNT 
pathways, with a gradual increase in the number of differentially regulated genes 
during progression of tissue damage. Disease phenotype, as well as differential 
regulation of select components of the hedgehog, canonical WNT and WNT-Ca2+ 
signaling pathways could be verified by quantitative PCR (qPCR) and 
immunohistochemistry. Treatment with 13cRA, not only attenuated disease 
progression, but even reversed early effects of CAD. The overall effects of the 
treatment are mediated by a potentially direct influence on fibrosis and inflammation 
associated gene expression, as well as by a specific modulation, observed for 
hedgehog and WNT pathway activations. The results identify a series of potential 
pathways that may represent therapeutic targets in chronic allograft dysfunction. 
Zusammenfassung 
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Zusammenfassung 
Die chronische Transplantat Dysfunktion (CAD), als Folge einer 
Nierentransplantation, ist charakterisiert durch voranschreitende Fibrose begleitet 
von einem entzündlichen Infiltrat. Um Veränderungen auf transkriptomischer Ebene 
im Krankheitsverlauf der CAD zu untersuchen wurde ein renales Transplantations-
Modell verwendet, in dem Fisher344(RT1lvl)-Rattennieren in Lewis(RT1l) Ratten 
transplantiert wurden. Zusätzlich dazu sollten die Mechanismen untersucht werden, 
die dem zuvor beobachteten therapeutischen Effekt einer Isotretionin-Behandlung 
der Ratten nach Transplantation zugrunde liegen. Die Charakterisierung des 
Transkriptoms wurde durchgeführt unter der Verwendung von Affymetrix Microarrays, 
von den Zeitpunkten null (untransplantierte Kontrollen), 7, 14 und 56 Tagen nach 
Explantation. Ein chronischer Schaden, begleitet von einem entzündlichen Infiltrat 
wurde 56 Tage nach Explantation im Tiermodel beobachtet. Regulatorische 
Signalwege wurden mit Hilfe der Database for Annotation, Visualization, and 
Integrated Discovery (DAVID) und basierend auf Signalwegen der Kyoto 
Encyclopedia of Genes and Genomes (KEGG) Datenbank identifiziert. 
In der Microarray-Analyse zeigten sich deutliche Veränderungen der Genexpression 
von Entzündungs- und Fibrose-assoziierten Genen. Desweiteren wurden 
Veränderungen beobachtet die Hedgehog- und WNT-Signalwege betreffend, mit 
einem steten Anstieg der Anzahl differentiell regulierter Gene während des 
Krankheitsverlaufs. Die differentielle Regulation sowohl Krankheits-assoziierter Gene 
als auch bestimmter Komponenten des Hedgehog-, kanonischen WNT- und WNT-
Ca2+ -Signalweges konnte mittels quantitativer PCR (qPCR) und teilweise auch auf 
der Proteinebene verifiziert werden. Die Isotretionin-Behandlung schwächte den 
Krankheitsverlauf nicht nur generell ab, sondern machte frühe Veränderungen sogar 
rückgängig. Die Effekte der Behandlung setzten sich aus einer möglicherweise 
direkten Beeinflussung der Fibrose bzw. Entzündung und einer spezifischen 
Modulation der beobachteten Aktivierung der Hedgehog- und WNT-Signalwege 
zusammen. Unsere Ergebnisse präsentieren Kandidaten für mögliche Zielgene einer 
Therapie der chronischen Transplantat Dysfunktion. 
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1 Introduction 
1.1 Chronic allograft dysfunction (CAD) 
Renal transplantation represents the only therapy option for individuals with end-
stage renal disease. While short-term graft survival increased and acute rejection 
decreased dramatically within the last 20 years, late graft loss remains to be a critical 
issue. Chronic allograft dysfunction (CAD) is a major long-term complication following 
kidney transplantation and is now the principle reason for loss of allografts [1]. CAD is 
a complex disease process resulting from the cooperation of humoral and cellular 
immune responses and nonimmunological factors [2-4]. Clinically, CAD is manifested 
by a gradual deterioration of renal function accompanied by hypertension and 
proteinuria [5]. 
 
Fig. 1: Kidney and Nephron. The left figure displays parts of the kidney and the nephron; 
1: Glomerulus, consisting of Bowman’s capsule and Glomerular capillaries, 2: Distal tubule;  
3: Proximal tubule, 4: Peritubular capillaries, 5: Descending limb of loop of Henle, 6: Ascending limb of 
loop of Henle, A: Renal vein, B: Renal artery, C: Ureter, D: Medulla, E: Pelvis, F: Cortex. From 
Freudenrich, Ph.D., Craig. "How Your Kidneys Work." 10 January 2001. 
http://www.howstuffworks.com/kidney.htm  
The right part of the figure originates from the “Sobotta Atlas of Human Anatomy” [6] and shows a 
section of a human kidney cortex. Staining with hematoxylin-eosin, 100x, P: Proximal tubule, G: 
Glomerulus, D: Distal tubule 
Histopathologically, CAD is characterized by hyalinosis and fibrosis of preglomerular 
vessels, transplant glomerulopathy, glomerulosclerosis, interstitial fibrosis with a 
variable degree of mononuclear cell infiltrates, and tubular atrophy [3, 4]. Importantly, 
many of the pathophysiologic features found in CAD can also be seen in other 
chronic fibrosing renal diseases such as diabetic nephropathy [7, 8]. 
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Thus, CAD can be regarded as a useful model for processes associated with 
progressive renal disease. Figure 1 shows the general compartments of the kidney in 
humans. 
1.1.1 Inflammation and fibrosis in CAD 
The kidney’s response to injury resembles a generalized wound healing response. 
The focus of wound healing is restoration of tissue architecture and recovery of 
function. For reasons that are not well understood, this is only partially successful in 
the adult [9]. In response to sustained inflammation fibrosis, an increased scarring of 
the tissue, is observed over time and is believed to be the central cause of the 
progressive decline and final loss of transplant in CAD [9]. A number of 
proinflammatory and fibrogenic mediators such as interleukin 6 (IL6; nomenclature 
for human protein symbols in accordance with the “Guidelines for human gene 
nomenclature” [10]), tumor necrosis factor alpha (TNFA), interferon gamma (IFNG) 
and transforming growth factor beta 1 (TGFB1) have been shown to be involved in 
various stages of the chronic inflammatory and reparative process [2]. 
There are indications that chemokines such as chemokine ligand 5 (CCL5) and 
interferon inducible protein 10 (CXCL10/IP10) also contribute to CAD [11]. These 
proteins are synthesized and secreted by tissue-infiltrating inflammatory cells as well 
as by activated graft parenchymal cells [4]. 
1.1.2 Myofibroblasts 
Fibrosis is associated with an excess synthesis of extracellular matrix (ECM), usually 
collagen. During renal fibrosis ECM is produced by activated fibroblasts, so called 
myofibroblasts, as evidenced by their de novo synthesis of alpha smooth muscle 
actin [12]. The origin of myofibroblasts in chronic renal fibrosis is a matter of 
conjecture. It has been suggested that myofibroblasts migrate either from the 
perivascular regions [13] or that their progenitors are recruited from bone marrow 
[14]. An emerging paradigm suggests that myofibroblasts may also originate from 
either the transition of tubular epithelial cells via epithelial to mesenchymal transition 
(EMT) [15], or by the transformation of resident fibroblasts [16]. EMT would be 
consistent with the hypothesis that a recapitulation of developmental programs is 
activated in response to tissue injury [9]. During EMT, epithelial cells have been 
described to loose polarity and cell-cell contacts, and to acquire mesenchymal cell 
expression profiles, and a migratory phenotype [9]. 
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1.1.3 Pathways activated in epithelial to mesenchymal transition (EMT) 
To better understand and potentially prevent organ loss due to chronic fibrosis, it is 
important to identify the underlying molecular mechanisms that drive these 
processes. Complex signal transduction between resident kidney cells and the 
infiltrate takes place and orchestrates changes in the phenotype of the kidney cells. If 
it was possible to correlate changes in the signal transduction to pathology one would 
possess a tool for manipulating early stages of the disease and might be able to 
change the outcome. 
 
Fig. 2: Pathways in EMT. This figure overviews crosstalk of pathways discussed in the context of 
EMT, including HEDGEHOG, WNT, JAK-STAT/PDGF, MAPK, NOTCH and TGFB pathways 
(discussed in 1.1.3). Boxes indicate gene products of canonical signaling of the individual pathways. 
Colors are uniform for the pathways and the target genes. Transcriptional activation of pathway genes 
leads to protein interaction, subsequently, target gene transcription. Arrows indicate positive 
interaction of gene products, symbols are used as defined in Abbreviations. Modified from [17]. 
Since in wound healing and fibrosis, steps of development seemed to have been 
recapitulated, it is not surprising that many of the signal transduction pathways, 
discussed in the context of EMT and fibrosis, were originally identified in 
developmental biology. 
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1.1.3.1 The TGFB pathway 
 
Fig. 3: The TGFB pathway. The diagram displays the main components of canonical TGFB 
signaling (discussed in detail in 1.1.3.1). Boxes indicate gene products, arrows indicate positive 
interaction of gene products, and the circle represents additional molecules involved. The white box 
indicates possible crosstalk with other pathways. Other symbols are used, as defined in Abbreviations. 
After binding of TGFB1,2,3 to the receptors TGFBRI/II signal transducers (SMAD) are activated and 
translate the signal into the nucleus. TGFB1,2,3-induced transcription factors bind to the DNA and 
activate transcription of TGFB1,2,3 target genes, one example of a TGFB1 target gene is PAI1. This 
scheme is a modification from the KEGG database pathway view 
(http://www.genome.jp/kegg/kegg2.html). 
TGFB1 is a secreted cytokine that regulates embryonic development and adult tissue 
homeostasis [18]. The TGFB family includes TGFB1, TGFB2 and TGFB3. The 
ligands bind to heteromeric complexes of type I and II receptor serine/threonine 
kinases (TGFBRI, TGFBRII) [19]. This leads to phosphorylation and activation of the 
TGFBRI. This pathway signals via phosphorylation of cytoplasmic SMAD proteins. 
The SMAD proteins are homologs of the drosophila protein “mothers against 
decapentaplegic” (Mad) and the C. elegans protein SMA. SMADs are divided into two 
types, the receptor-regulated SMADs (rSMADs) and the coSMADs. In the TGFB 
pathway, signaling is mediated by the rSMADs SMAD2 and SMAD3, as well as the 
coSMAD SMAD4. The phosphorylated rSMADs bind a coSMAD with high affinity and 
enter the nucleus as rSMAD/coSMAD complex. The complex binds to cofactors or 
promoters and regulates the transcription of DNA. 
Alternative signaling of TGFB include the mitogen-activated protein kinase (MAPK) 
and protein kinase B (PKB) pathways [20]. TGFB1 is a major mediator of renal 
fibrosis [21, 22] [23] and known to stimulate EMT in vitro [24]. Figure 3 summarizes 
the basic steps in canonical TGFB signaling. 
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1.1.3.2 The NOTCH pathway 
 
Fig. 4: The NOTCH pathway. The diagram displays the main components of the NOTCH signaling 
pathway (discussed in detail in 1.1.3.2). Boxes indicate gene products, arrows indicate positive 
interaction of gene products, and the circle represents additional molecules involved. Other symbols 
are used as defined in Abbreviations. After the binding of DELTA to NOTCH, the intracellular domain 
of NOTCH is cleaved and enters the nucleus. The intracellular domain can, involving further signaling 
steps, activate transcription factors of the HES family. This scheme is a simplified modification from 
the KEGG database pathway view. 
The notch gene was discovered almost 90 years ago, but only in the early eighties 
was it identified to encode a single-pass transmembrane receptor. Vertebrates 
possess four different notch receptors, referred to as NOTCH1 to NOTCH4 and five 
transmembrane ligands: jagged 1, jagged 2, delta-like 1, delta-like 3, and delta-like 4 
(JAG1, JAG2, DLL1, DLL3 and DLL4). NOTCH signaling is activated upon cell-to-cell 
contact as a result of interactions between NOTCH receptors and their ligands. At the 
molecular level, triggering of NOTCH receptor by ligand binding promotes two 
proteolytic cleavage events at the NOTCH receptor that result in the separation of the 
NOTCH intracellular domain (NICD) into the cytoplasm. NICD cannot directly bind to 
DNA but instead, heterodimerizes with the recombination signal sequence-binding 
protein Jk (RBP-J). NICD first displaces corepressors from RBP-J, resulting in de-
repression of promoters containing RBP-J binding sites and subsequently, recruits a 
coactivator complex to activate transcription of NOTCH target genes [25]. The 
hairy/enhancer of split (HES) genes are highly conserved proteins that are regulated 
by NOTCH in multiple cell types [26]. These transcription factors are the best-
described NOTCH target genes [27]. NOTCH pathway activation has been observed 
in the pathogenesis of glomerular diseases [28] and in EMT in development and 
tumorgenesis [29, 30]. Figure 4 summarizes the basic steps in canonical NOTCH 
signaling. 
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1.1.3.3 The hedgehog (HH) pathway 
 
Fig. 5: The hedgehog pathway. The diagram displays the main components of canonical HH 
signaling (discussed in detail in 1.1.3.3). Boxes indicate gene products, arrows indicate positive 
interaction of gene products, and the circle represents additional molecules involved. The white boxes 
indicate possible crosstalk with other pathways. Other symbols are used as defined in Abbreviations. 
After binding of HH to the receptor PTCH, the inhibition of the SMO receptor is relieved. Subsequent 
activation of GLI transcription factors leads to nuclear enrichment of GLI and activation of transcription 
of Hedgehog target genes such as the receptor PTCH. This scheme is a simplified modification from 
the KEGG database pathway view. 
Mammals have three secreted hedgehog (HH) protein isoforms: sonic (SHH), indian 
(IHH) and desert (DHH). The HHs bind to their receptors patched 1 or 2 (PTCH1, 
PTCH2) which then release their repression of the 7-transmembrane protein 
smoothened (SMO). SMO regulates activity of the HH specific transcription factors 
GLI family zinc finger 1, 2 and 3 (GLI1, GLI2 and GLI3) by stabilizing the GLIs and 
stopping the GLI-inhibitor suppressor-of-fused (SU(FU)). Stabilized GLIs can enter 
the nucleus and activate transcription of HH target genes [31]. Similar to the other 
pathways discussed here, the HH pathway also plays critical roles in development 
and in adult tissue homeostasis. Moreover, this pathway has been discussed in the 
context of tissue repair during chronic persistent inflammation and EMT in 
tumorgenesis [17, 31]. In a mouse model, HH could be demonstrated to be essential 
for normal wound healing [32]. In addition to patched, the so called megalin receptor 
(LRP2/Megalin) has been shown to bind SHH and mediate endocytosis [33, 34]. 
Figure 5 summarizes the basic steps in canonical HH signaling. 
Megalin is a large (600 kDa), single spanning transmembrane glycoprotein which 
belongs to the low-density lipoprotein receptor family [35]. Megalin is an endocytotic 
scavenger receptor that mediates non-specific uptake of protein [36] (see figure 6) 
and is internalized after ligand binding. This receptor is of special interest, because it 
is expressed in cells of the kidney proximal tubule brush border, in addition to its 
association with the HH pathway. Also, megalin expression is put into context with 
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the TGFB pathways and seems to play an important role in chronic kidney diseases 
[37-39]. 
 
Fig. 6: LRP2/Megalin. The scheme gives an overview of the LRP2/Megalin localization within the 
renal nephron, as a functional unit of the kidney. After glomerular filtration; the primary excretion fluid 
is channeled through the tubule and through active transport, or passive processes along the tubule, 
the urine is generated. Megalin is an endocytotic scavenger receptor of the proximal tubule that binds 
low weight molecules such as certain proteins or vitamins and transports them from the apical side of 
the tubule cells to the basal side. The scheme is adapted from ReceptIcon Aps (www.recepticon.com). 
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1.1.3.4 The WNT pathway 
 
Fig. 7: The canonical WNT pathway The diagram displays the main components of canonical 
WNT signaling (discussed in detail in 1.1.3.4). Boxes indicate gene products, arrows indicate positive 
interaction of gene products, and the circle represents additional molecules involved. The white boxes 
indicate possible crosstalk with other pathways. Other symbols are used as defined in Abbreviations. 
After binding of WNT to the receptor frizzled degradation of CTNNB1 is inhibited, resulting in nuclear 
enrichment of CTNNB1. Complexes of CTNNB1 and WNT-dependent transcription factors such as 
LEF1 bind to the DNA and activate WNT target genes expression. Known targets are amongst others 
FN1, MMP7 and CD44. This scheme is a simplified modification from the KEGG database pathway 
view. 
Two decades ago investigators discovered the homology between the Drosophila 
wingless gene (wg) and the vertebrate oncogene integrase 1 (INT1). They named the 
family of secreted glycoproteins, known as WNTs (wg-INT1s). To date 19 WNT-
proteins have been identified in human, mouse and rat. Members of the WNT 
superfamily activate at least three distinct pathways. The WNT pathways, originally 
characterized as essential components in early development, are implicated in many 
physiological and pathophysiological processes. It has been proposed that WNT 
signaling may be recapitulated in the progressive damage associated with chronic 
organ failure [40]. Of the three WNT pathways, canonical WNT, WNT-Ca2+ and WNT 
planar cell polarity, the canonical WNT pathway, acting through activation of beta-
catenin (CTNNB1), is best understood. In the absence of WNT, CTNNB1 becomes 
phosphorylated and then degraded by the proteasome. If select WNT proteins bind to 
so called frizzled receptors (FZD), the resulting signaling cascade inhibits CTNNB1 
degradation, leading to beta-catenin accumulation in the nucleus, where the 
CTNNB1-T-cell specific transcription factor (CTNNB1-TCF) complex activates Wnt 
target gene transcription. 
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Fig. 8: The WNT-Ca2+ pathway The diagram displays the main components of WNT –Ca2+ 
signaling (discussed below). Boxes indicate gene products, arrows indicate positive interaction of gene 
products, and the circle represents additional molecules involved. Other symbols are used as defined 
in Abbreviations. After binding of WNT to the FZD receptor, activation of phosholipase C, calmodulin 
kinase II and protein kinase C is involved in the signaling process. Ca2+-dependent signaling finely 
leads to activation of transcription factors of the NFAT-family. This scheme is a simplified modification 
from the KEGG database pathway view. 
The WNT-Ca2+ pathway acts in a beta-catenin independent manner, through 
calmodulin kinase II, protein kinase C, and the subsequent activation of transcription 
factors of the nuclear factor of activated T-cells (NFAT) family [41]. Figure 8 
summarizes the basic steps in WNT-Ca2+ signaling. 
 
Fig. 9: The WNT planar cell polarity pathway The diagram displays the main components of 
WNT–PCP signaling (discussed below). Boxes indicate gene products, arrows indicate positive 
interaction of gene products, and the circle represents additional molecules involved. Other symbols 
are used as defined in Abbreviations. This scheme is a simplified modification from the KEGG 
database pathway view. 
The third pathway, the WNT planar cell polarity (PCP) pathway signals independently 
from beta-catenin. The PCP pathway activates either the ras homologue gene-family 
member A (RHOA) – Rho-associated coiled-coil-containing protein kinase (ROCK) 
pathway, or signals through Jun N-terminal kinases (JNK) and is thought to regulate 
changes in the cytoskeleton [42, 43]. Figure 9 summarizes the basic steps of the 
WNT planar cell polarity pathway. Based on the proposed targets of these pathways, 
each could potentially contribute to pathophysiologic events associated with fibrosis. 
Introduction 
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1.2 Preceding experiments 
1.2.1 CAD in a Fisher to Lewis rat model 
In the original Fisher to Lewis rat renal allograft model as described by Lee et al. [44], 
Fisher kidneys were transplanted into Lewis rats. These rat strains differ in their 
major histocompatibiliy complex (RT1) RT1-C/E/M region. The Fisher strain 
represents the RT1lvl and the Lewis strain the RT1l haplotype variant of the  
RT1-C/E/M region [45, 46]. This model also made use of low doses of cyclosporine A 
and right kidney nephrectomy seven to ten days after transplantation. Without the 
right, healthy kidney, the recipient animal is soley dependent on the function of the 
allograft. We, and others, have reported that this allograft model does not show 
evidence of CAD, including rejection in preglomerular vessels, glomeruli and 
tubulointerstitium, and displays only small areas of unspecific acute and chronic 
fibrosing lesions, probably due to ischemia reperfusion injury and surgical trauma [5, 
47, 48]. To this end a modification of this model was used. Cyclosporine A and right 
nephrectomy of the recipient’s own kidney were omitted after kidney transplantations 
from Fisher to Lewis rats, performed in collaboration with Prof. Herrmann-Josef 
Gröne (Deutsches Krebsforschungszentrum Heidelberg) [5]. These modifications of 
the model were found to lead to a well-defined, acute phase (day 0 to day 14) of 
vascular rejection manifested in endothelialitis, interstitial rejection with tubulitis, and 
transplant glomerulitis [5, 47, 49]. Importantly, during the chronic rejection-phase of 
this modified model (day 14 to day 56), morphologic phenomena, characteristic of 
allograft rejection in humans, are observed. The preglomerular arteries show an 
increase in subendothelial matrix and an infiltration of the subendothelium and media 
by mononuclear cells (displayed in figure 10). Due to immunosuppression this latter 
phenomenon is only seen in relatively few cases of human allografts with CAD. 
Transplant glomerulopathy, as well as changes in the tubulointerstitium that are 
characteristic of CAD show tubular atrophy and matrix increase, as well as focal low 
level tubulitis in differentiated tubules (see figure 10). In summary, major morphologic 
phenomena commonly observed during the progression of CAD in patients can be 
documented in this model. 
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Fig. 10: Allograft morphology. Periodic-acid Schiff (PAS) staining was performed on kidney 
sections by Ms. Gabrielle Schmidt from the DKFZ, Heidelberg, as described in 4.3.1. A-D: figures A to 
D display transplant glomerulopathy (A- human, B- fisher to lewis (FL) rat- allografts; C,D - are higher 
magnifications. The glomeruli show mesangial matrix expansion. The capillary walls are thickened and 
focally duplicated with few adherent mononuclear cells in the capillary lumen (glomerulitis). The 
surrounding tubulointerstitium presents chronic changes such as tubular atrophy and interstitial 
fibrosis, with an additional inflammatory cell infiltrate. E, F: figures E and F display chronic vascular 
rejection (E- human, F- FL rat- allograft). Arteries show an increase in the subendothelial matrix, with a 
severe obliteration of the vessel lumen and an infiltration of the subendothelium and media by 
mononuclear cells. Numbers range from few cells in the human (E) to more prevalent ones in the rat 
(F) (A,B and E,F: 200x; C,D: 400x). 
1.2.2 Effects of retinoic acid treatment 
In order to find alternatives to the conventional immunosuppressive therapies, the 
effect of retinoic acid to prevent allograft rejection was tested in this model. 13-cis-
retinoic acid (13cRA) has been reported to ameliorate rejection phenomena and to 
preserve graft function in acute models of renal transplantation [50]. Based on these 
results, it was hypothesized that 13cRA could prevent or moderate CAD. 
The anti-inflammatory and anti-proliferative actions of retinoids (derivatives of vitamin 
A) have long been known [49]. The receptors of retinoids belong to the superfamily of 
nuclear receptors (NRs). NRs form a class of transcription factors regulated by 
steroids, thyroid hormone, retinoids and vitamin D [51]. Retinoids act via retinoic acid 
(RAR) and retinoid X (RXR) receptors, with alpha, beta and gamma subtypes. RAR 
and RXR receptors are widely expressed in the rat and human kidney as well as in 
immune cells such as B and T cells and monocytes/macrophages [52-54]. 
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Type 1 nuclear receptors are characterized by the formation of homodimers and 
include, amongst others, the estrogen receptor. Type 2 nuclear receptors are 
characterized by the formation of retinoic X receptor heterodimers and include, 
amongst others, the RAR, RXR and peroxisome-proliferators-activated-receptor 
(PPAR). Hetero-dimerization increases diversity in the signaling of nuclear receptors. 
The retinoid receptors regulate expression of target genes, either by direct binding to 
retinoic acid response-elements, or indirectly, by diverse mechanisms called 
transactivation or transrepression. They are known to influence transcription factors 
such as activator protein-1 (AP-1) [55] and nuclear factor-kB (NF-kB) [56]. 
In experimental models of glomerulonephritis, retinoids have been shown to inhibit 
proliferation of mesangial cells, lower the number of infiltrating monocytes, and 
reduce extracellular matrix deposition without signs of vitamin A toxicity [57, 58]. 
A dose of 2 mg 13cRA/kg body weight/day, corresponding to a dose used in humans, 
was tested by Prof. Gröne’s laboratory as a potential treatment modality in the 
modified Fisher to Lewis model of rat renal transplantation. The 13cRA was 
administered orally starting on the day of transplantation. On day 56 after 
transplantation, a significant preservation of renal function could be observed, while 
the placebo group showed characteristic histological changes of CAD in the allografts 
as early as 4 weeks. Morphometric analysis showed inhibition of subendothelial 
fibrosis. Morphology of glomerular structures was preserved. Infiltration of monocytes 
and CD8+ T-cells was still observed but to a significantly lesser degree. The mRNA 
expression of inflammatory cytokines/chemokines was significantly lower in the 
13cRA treated animals [5]. 
1.2.3 Working mechanism of retinoic acid 
Retinoic acid could have a protecting effect on cells of the grafted kidney as well as 
on immune cells, preventing alloreactivity. Adams et al. further investigated the 
working mechanism of the 13cRA on the DNA level. TNFA - mediated activation of 
CCL5 gene expression can be inhibited by 13cRA. Truncated reporter constructs 
showed that action of 13cRA is not necessarily mediated through direct binding to 
DNA, since deletion of the consensus sequences did not influence 13cRA 
suppression of CCL5 promoter activity [5]. In 2005, Pascual et al. [59] identified a 
novel molecular pathway of nuclear receptor mediated transrepression. The 
peroxisome proliferator-activated receptor gamma (PPARG) is a member of the 
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nuclear receptor family, as well as a receptor for retinoic acid [60]. It could be 
demonstrated that the PPARG receptor represses the transcriptional activation of 
inflammatory-response genes. 
 
Fig. 11: Transrepression mechanism of PPARG. This scheme displays the basic mechanisms 
underlying the transrepression of NOS2 transcription activation by PPARG, as identified by Pascual et 
al (discussed in 2.1.2). Through sumoylation of the PPARG receptor, the nuclear corepressor complex 
(NCOR) is retained at the NOS2 promoter, leading to an inhibition of NOS2 transcription, despite an 
inflammatory (LPS) stimulus. 
Lipopolysaccaride (LPS) triggered-activation of the inducible nitric oxide gene 
(NOS2) in mouse macrophages could be inhibited by simultaneous stimulation with a 
PPARG agonist. In the absence of inflammatory stimulation, NOS2 transcription is 
repressed by a complex of proteins containing the nuclear receptor corepressor 
(NCOR). After stimulation, this complex is degraded by the proteasome and replaced 
by an activator complex, subsequently, transcription can take place. Pascual et al. 
showed that after ligand binding a posttranscriptional modification of the PPARG 
receptor takes places. The PPARG is sumoylated and subsequently recruited to the 
NCOR complex at the NOS2 promoter. This leads to a repression of the proteasomal 
degradation of the NCOR and transrepression of NOS2 gene transcription. The basic 
steps of this mechanism are displayed in figure 11. 
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An indirect Transrepression mechanism identical or similar to the mechanism 
identified by Pascual et al. might be responsible for the inhibition of gene expression 
of inflammatory mediators such as CXCL10/IP10, as observed by Adams et al. in the 
retinoic acid treated animal group. 
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2 Aim of the present study 
2.1 Transcriptomic profiling of kidney transplants 
The goals of the present study were twofold. First, to characterize by transcriptomic 
analysis, the development of CAD in the rat animal-model over specified time points 
by studying changes in exemplary, regulatory pathways previously associated with 
fibrosis and EMT. For studying complex biological events, the evaluation of single 
gene expression is generally inferior to a multi-gene analysis. This is also true in the 
context of signal transduction whereby a higher interpretation scale of the study can 
be achieved. It was hypothesized that it is possible to identify changes in the 
activation status of distinct pathways leading to the induction and progression of 
chronic renal allograft dysfunction. 
The second aim of the study was to identify potential therapeutic modes of action of 
13cRA in chronic renal fibrosis through analysis of alterations in the same regulatory 
pathways.  
Microarray experiments, analyzed with new bioinformatics approaches and expanded 
pathway analysis, provided the basis for these studies. Quantitative PCR (qPCR) 
was used to verify gene expression of genes assigned to the microarray, and to 
investigate additional genes not present on the array. Additionally, 
immunohistochemistry (IHC) for select candidates was employed to demonstrate 
translation of changes on the mRNA into changes on the protein level. 
It was further hypothesized that the same, or a similar molecular transrepression 
mechanism, as observed by Pascual et al. in macrophages, leads to the reduced 
expression of inflammatory genes observed in vivo after 13cRA treatment and in vitro 
after stimulation of fibroblasts. To this end the ChIP technique was established in our 
lab and experiments on human fibroblasts performed. 
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3 Material 
For general statements, gene and protein nomenclature was employed according to 
the “Guidelines for Human Gene Nomenclature” [10]. Gene and protein symbols are 
all uppercase, gene symbols are italicized. No greek symbols are used. 
For the transcriptomic profiling, nomenclature for genes and proteins was employed 
according to the “Guidelines for Nomenclature of Genes, Genetic Markers, Alleles, 
and Mutations in Mouse and Rat” by the “Rat Genome and Nomenclature 
Committee” revised, January 2009. Gene symbols begin with an uppercase letter 
(not a number), followed by italicized lowercase letters. Protein symbols are not 
italicized. 
3.1 Microarrays 
Microarrays of transplanted kidneys  
Time points Treatment Animal number 
Control kidney day 0, n=3  N3 
   N4 
   N5 
Transplanted kidney 7d, n=4 Placebo 211 
  Placebo 213 
  Placebo 539 
  Placebo 540 
Transplanted kidney 14d, n=5 Placebo 244 
  Placebo 246 
  Placebo 531 
  Placebo 546 
  Placebo 248 
Transplanted kidney 56d, n=5 Placebo 572 
  Placebo 574 
  Placebo 592 
  Placebo 593 
  Placebo 587 
Transplanted kidney 7d, n=4 13cRA 1448 
  13cRA 1464 
  13cRA 1466 
  13cRA 1357 
Transplanted kidney 14d, n=5 13cRA 561 
  13cRA 563 
  13cRA 564 
  13cRA 527 
  13cRA 760 
Transplanted kidney 56d, n=4 13cRA 1083 
 13cRA 1129 
 13cRA 1131 
 13cRA 1132 
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To assess changes, observed in the study of Adams et al. [5] performed in the 
laboratory of Prof. H.-J. Gröne, on the transcriptomic level, microarray expression 
data was generated. Total RNA was extracted from the transplanted (left) kidney 
allografts by the method of Chomczynski and Sacchi as in described [61]. The 
recipient’s right native kidney was not investigated. 
Microarray analyses were performed in cooperation with Prof. Gretz at the Zentrum 
für Medizinische Forschung, Mannheim (ZMF). Samples were hybridized to 
Affymetrix RG-U34A microarrays and scanned with an Affymetrix scanner controlled 
by the Affymetrix® GeneChip® Operating Software (GCOS). All reactions were 
performed essentially according to the Affymetrix protocol (Affymetrix, Sunnydale, 
CA). A total of 30 arrays were generated, as detailed above.  
3.1.1 CEL files 
Affymetrix microarray experiments are evaluated using the GCOS software. GCOS 
interfaces with equipment to run a probe-array experiment, and is also used to 
generate preliminary analysis data from an experiment. The basic files generated by 
GCOS are the “Experiment File”, “Image Data File”, and “Cell Intensity File”. 
Experiment File *.EXP: This file contains the parameters of the experiment, such as 
probe-array type, experiment name, equipment parameters, sample description, and 
others. This file is not used for analysis, but is required to open other GCOS files for 
the designated chip experiment. 
Image Data File *.DAT: This is an image file generated by the scanner from the 
probe array after processing on the fluidics station. This file can be viewed in GCOS 
to assess the quality of scanning event or exported as a *.TIFF image. It is used in 
GCOS to generate the *.CEL file (see following). 
Cell Intensity File *.CEL: This binary file is the result of low level analysis performed 
from the *.DAT image file. It is exported from GCOS and is often used as the base 
file for further analysis. 
A digital version of these files was given to us by Prof. Gröne and subsequent 
analyses of the CEL files were performed in the lab of the AG Dr. Peter Nelson, 
Klinische Biochemie, Medizinische Poliklinik der LMU. 
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3.2 Kidney samples 
3.2.1 RNA isolated from kidney sections 
The RNA samples that built the basis of this thesis were provided by our long term 
collaborator Prof Dr. Hermann-Josef Gröne.  
Prof Dr.Hermann-Josef Gröne is head of the Department of Cellular and Molecular 
Pathology at the DKFZ in Heidelberg. The major focus of his research is renal 
physiology and the pathophysiology of renal disease. Over the past ten years he has 
co-authored 25 papers with PD Dr. Nelson including a series of studies detailing the 
biology of acute and chronic allograft rejection using the model system as described 
in the thesis. RNA provided by Prof. Gröne was isolated by the method of 
Chomczynski and Sacchi and quality controlled as described in [5]. In Munich RNA 
quality was additionally monitored by agarose electrophoresis for degradation. No 
degradation could be observed and samples were stored at -80°C. 
3.2.2 Kidney sections for immunohistochemistry 
Tissue sections were prepared as described in [5]. 
 
Subsequent sample preparation was performed in the laboratory of PD Dr. Peter 
Nelson, Klinische Biochemie, Medizinische Poliklinik der LMU. 
3.3 Cells 
3.3.1 Human fibroblast cell line K4IM 
The human fibroblast cell line K4IM, immortalized with the SV40 T large antigen, was 
generously donated by Professor Haas, Freiburg. This cell line was established in 
order to study the mechanisms that induce and maintain synovial fibroblast activation 
[62]. Haas et al. used synoviocytes from a healthy donor and generated the stable 
synovial fibroblast cell line K4IM with the help of SV40 T antigen mediated 
immortalization. Analyzing the expression of cell surface markers in the native 
parental synoviocyte line K4WT, and in the immortal K4IM cells, demonstrated that 
K4IM cells differ only in part from the parental K4WT phenotype [62]. Therefore, the 
immortalized K4IM cell line is an ideal tool to study mechanisms that maintain 
fibroblasts activation during fibrosing and inflammatory diseases [62]. 
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3.3.2 Media used for K4IM 
K4IM cells were cultured in culture medium consisting of Dulbecco's Modified Eagles 
Medium (DMEM, Invitrogen, Karlsruhe) supplemented with 10% heat inactivated FBS 
(Biochrome AG, Berlin) and 1% of Penicillin/Streptomycin (see 3.9). 
As freezing medium, culture medium with the addition of DMSO to a final 
concentration of 10% was used.  
Starving medium equals culture medium without the addition of FBS. 
3.4 Oligonucleotides 
Supplemental figure 1 summarizes all the oligonucleotides employed in this study, 
including sequences. Self-designed oligonucleotides were synthesized by Metabion, 
Martinsried. 
3.4.1 Oligonucleotides for qPCR of cDNA 
qPCR was performed using either Assays on Demand (AoD) (Applied Biosystems, 
Darmstadt), pre-developed reagents for 18S rRNA (Applied Biosystems, Darmstadt) 
or a SYBR green system using self designed primer pairs as well as QuantiTect 
Primer Assays (Qiagen, Hilden). 
3.4.1.1 AoD Assays  
Probes of the AoDs were labeled 5-prime with 6-Carboxy-Fluorescein (FAM) and 3-
prime with the quencher Tetramethyl-Rhodamin (TAMRA). The probe of the 
housekeeping gene 18S rRNA was labeled 5-prime with VIC® (Trademark) and 3-
prime with the quencher (TAMRA). All primers and probes were provided by the 
manufacturer as 20x assay solutions. 
3.4.1.2 QuantiTect Primer Assays  
Each assay for a specific gene was supplied as a lyophilized mix of forward and 
reverse primers and was reconstituted in water to obtain a 10x assay solution, 
according to the manufacturers instructions. Information about concentrations was 
not provided.  
3.4.1.3 Oligonucleotides for qPCR, self-designed 
Lyophilized oligos are reconstituted in water to reach a 100 pmol/ µl stock solution. 
The working solution contains primers in a concentration of 10 pmol/µl. 
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3.4.2 Oligonucleotides for PCR of genomic DNA, self designed 
Lyophilized oligos are reconstituted in water to reach a 100 pmol/µl stock solution. 
The working solution contains primers in a concentration of 10 pmol/µl. 
3.5 Enzymes, enzyme solutions, and inhibitors 
DNAse I  Qiagen, Hilden 
Protease XXIV (7-14U/mg), lyophilized Sigma-Aldrich, Taufkirchen 
Protease inhibitor cocktail, complete  Roche Diagnostics, Mannheim 
(No 04693116001) Stock solution (50x) 
Protease K (20 mg/ml) Sigma-Aldrich, Taufkirchen 
RNase A (10 mg/ml) Roche Diagnostics, Mannheim 
Taq DNA – polymerase (5U/µl) NEB, Frankfurt a.M. 
Trypsin – EDTA PAA Laboratories, Pasching, Austria 
SuperscriptTM II Reverse Transcriptase Invitrogen, Karlsruhe 
3.6 Antibodies 
3.6.1 Primary antibodies 
Mouse anti-rat beta-catenin BD Bioscience, Heidelberg 
Mouse anti-rat Cd44 H (clone OX-49) BD Bioscience, Heidelberg 
Rabbit anti-rat collagen I Chemicon, Temecula, USA 
Rabbit anti-human fibronectin  DAKO, Glastrup, Denmark 
Rabbit anti-acetyl histone (H3, Lys9/18) Upstate, Lake Placid, USA 
Rabbit anti-rat Lef1 Cell Signaling (NEB), Frankfurt a.M. 
Rabbit anti-NCOR ChIP grade Abcam, Cambridge, UK 
3.6.2 Secondary antibodies 
Biotinylated goat anti-mouse IgG (H+L) Jackson ImmunoResearch 
 Laboratories, West Grove, USA 
Biotinylated goat anti-Rabbit IgG (H+L)  Jackson ImmunoResearch 
 Laboratories, West Grove, USA  
3.7 Kits 
AEC Substrate kit Biogenex, San Ramon, USA 
Avidin/Biotin Blocking kit Vector Laboratories, Burlingame, 
 USA 
DuoSet RANTES ELISA Development kit  R&D Systems Europe, Wiesbaden 
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Quant-iTTM RNA Assay kit Invitrogen, Karlsruhe 
RNeasy Mini (50) kit Qiagen, Hilden 
RNase – free DNase Set (50) Qiagen, Hilden 
Taqman® Universal PCR Master mix  Applied Biosystems, Darmstadt 
VECTASTAIN® Universal Quick kit Vector Laboratories, Burlingame, 
 USA 
3.8 Chemicals, reagents, and additives 
13-cis retinoic acid (13cRA) Sigma Aldrich, Taufkirchen 
3,3'-diaminobenzidine (DAB) Sigma Aldrich, Taufkirchen 
Acetic acid Sigma Aldrich, Taufkirchen 
Acrylamid, linear Ambion/Applied Biosystems, 
 Darmstadt 
Agarose, ultrapure Invitrogen, Karlsruhe 
Aqua ad injectabilia Braun, Melsungen 
ß-mercaptoethanol (BME) Roth, Karlsruhe 
Boric acid Merck, Darmstadt 
Bovine serum albumin (BSA), PCR grade Fermentas, St.Leon-Rot 
Chloroform/isoamyl alcohol (49:1) Merck, Darmstadt 
Deoxycholic acid Sigma Aldrich, Taufkirchen 
Dimethylsulfoxid (DMSO) Merck, Darmstadt 
Dithiothreitol (DTT) Invitrogen, Karlsruhe 
Ethanol (EtOH) Merck, Darmstadt 
Ethylenediaminetetraacetic acid (EDTA) Calbiochem, Darmstadt 
Ethidium bromide solution, 1.0% (EtBr) Merck, Darmstadt 
Fetal bovine serum (FBS)  Biochrome AG, Berlin 
Formaldehyde, pro analysis, 37% Merk, Darmstadt 
Glycine AppliChem, Darmstadt 
Glycogen Ambion/Applied Biosystems, 
 Darmstadt 
Herring sperm DNA  Roche Diagnostics, Mannheim 
Hexanucleotides Roche Diagnostics, Mannheim 
Hydrogen peroxide solution, 30% Merck, Darmstadt 
KCl Merck, Darmstadt 
LiCl Merck, Darmstadt 
Methanol Merck, Darmstadt 
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Methyl green Fluka, Schnelldorf 
MgCl2 Fermentas, St.Leon-Rot 
NaCl Merck, Darmstadt 
NaHCO3 Roth, Karlsruhe 
NiCl Sigma Aldrich, Taufkirchen 
dNTP set Fermentas, St.Leon-Rot 
NP40 Fluka, Schnelldorf 
Piperazine-N,N-bis 2-ethanesulfonic acid Boehringer Mannheim, Mannheim 
(PIPES) 
RNAsin – ribonuclease inhibitor Promega, Madison, USA 
Rox reference dye (25x) Invitrogen, Karlsruhe 
Roti® –Phenole/C/I Roth, Karlsruhe 
Sodium-N-lauroylsarcosinate (Sarkosyl) Fluka, Schnelldorf 
Sodium acetate Merck, Darmstadt 
Sodium citrate Merck, Darmstadt 
Sodium dodecyl sulfate (SDS) Roth, Karlsruhe 
SYBRgreen I (250x) Fluka, Schnelldorf 
Pansorbin® cells (StaphA), lyophilized Calbiochem, Darmstadt 
Tnf alpha, recombinant, human ImmunoTools, Friesoythe 
Trishydroxymethylaminomethan (Tris) Merck, Darmstadt 
TritonX100 Sigma Aldrich, Taufkirchen 
Tween 20 Fluka, Schnelldorf 
Immumount Thermo Fisher Scientific, Bonn 
Xylol Merck, Darmstadt 
3.9 Buffers and Solutions 
Antibody diluent Dako REALTM DAKO, Glastrup, Denmark 
Antigen unmasking solution 0.1M Sodium citrate, pH 6.0  
Cell lysis buffer 5 mM PIPES pH 8.0, 85 mM KCl, 
 0.5% NP40 
Elution buffer 50 mM NaHCO3, 1% SDS (v/v) 
First-strand buffer (5x) Invitrogen, Karlsruhe 
Immuno precipitation (IP) dilution buffer 0.01% SDS (v/v), 1,1% TritonX100, 
 1.2 mM EDTA, 16.7 mM Tris pH 8.1, 
 167 mM NaCl 
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Dialysis buffer (1x) 2 mM EDTA, 0.2% Sarkosyl, 50 mM 
 Tris pH 8.1 
Streptavidin-Horseradish peroxidase Vector Laboratories, Burlingame, USA 
IP washing buffer 100 mM Tris pH 9.0, 500 mM LiCl, 
 1% NP40, 1% deoxycholic acid 
Loading buffer 0.25% Bromphenol blue, 0.25% 
 Xylene cyanol, 30% glycerol in H2O 
Mayers haemalaun Roth, Karlsruhe 
Nuclei lysis buffer 1% SDS (v/v), 10 mM EDTA, 50 mM 
 Tris pH 8.1 
Penicillin/Streptomycin (100x) Penicilin 10000U/ml,  
 Streptomycin 10mg/ml, 0.9% NaCl 
 PAA Laboratories, Pasching, Austria 
Phosphate buffered saline (PBS) (1X) PAA Laboratories, Pasching, Austria 
PBS/Tween PBS (1x), 0.5% Tween 20 
PCR Optimizer Bitop, Witten 
PK buffer (5x) 50 mM Tris pH 7.5, 25 mM EDTA, 
 1.25%, SDS (v/v) 
Protease XXIV solution 3-5U/ml in H2O 
SYBRgreen I solution 1:100 in H2O with 20% DMSO, -20°C 
SYBRgreen Mastermix 20% Taq buffer without detergent,  
 375 µM NTPs, 4% Rox referencedye, 
 40% PCR Optimizer, 2% BSA,  
 0.4% SYBRgreen I solution, 6 mM MgCl2 
Taq buffer without detergent (10x) Fermentas, St.Leon-Rot 
TBE (1x) 90 mM Tris, 2 mM Boric acid, 10 mM  
 EDTA pH 8.0, 0,015 % EtBr (v/v) 
TE buffer (1x) 10 mM Tris pH 7.5, 1 mM EDTA 
ThermoPol buffer (10x) NEB, Frankfurt a.M. 
Trypsin – EDTA solution PAA Laboratories, Pasching, Austria 
Trypan Blue Sigma Aldrich, Taufkirchen 
3.10  Consumables 
Cell culture plates  TPP AG, Trasadingen, Switzerland 
Cell culture flasks TPP AG, Trasadingen, Switzerland 
Cell scraper TPP AG, Trasadingen, Switzerland 
Falcon tubes 15 ml/ 50 ml BD Bioscience, Heidelberg 
Taqman plates Sarstedt, Nümbrecht 
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Taqman cover Sarstedt, Nümbrecht 
ELISA plate Maxisorb Nunc, Roskilde, Denmark 
3.11  Instruments 
ABIPrism7000 Sequence Detection System Applied Biosystems, Darmstadt 
Plate reader GENiosPlus Tecan, Crailsheim 
Gel electrophoresis apparatus MBT Brand, Gießen 
Geneamp PCR system 9700 PE Applied Biosystems, Darmstadt 
Incubator Modell 400 Brutmaschinen Janeschitz, 
 Hammelburg 
Liquid Blocker, Super Pap pen Daido Sangyo, Tokyo, Japan 
Leica microscope Q600 Qwin Leica, Cambridge, UK 
MinifugeT Heraeus, Hanau 
Megafuge 1.0R Heraeus, Hanau 
Micro Centrifuge 5415 D Eppendorf, Hamburg 
Microwave Milestone Medical, Kalamazoo, USA 
Neubauer counting chamber Braun, Melsungen 
Power supply PowerPac300 Biorad, München 
QubitTM fluorometer Invitrogen, Karlsruhe 
Thermomixer comfort Eppendorf, Hamburg 
Sonifier 250 Branson Ultrasonics Corporation, 
 Danbury, USA 
Steamer MultiGourmet Braun, Kronberg 
UV Transilluminator  Bachofer, Reutlingen 
Water bath Haake SWB20 Thermo Haake, Karlsruhe 
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3.12 Software 
3.12.1 Commercial software 
ABI Prism 7000 SDS Applied Biosystems, Darmstadt 
BiblioSphere Genomatix GmbH, München 
ChipInspector Genomatix GmbH, München  
Prism 4.03. GraphPad Software, La Jolla, USA 
Illustrator CS2 Adobe Systems, San Jose, USA 
Microsoft Office 2003 Microsoft, Redmont, USA 
Photoshop CS2 Adobe Systems, San Jose, USA 
XFluor Tecan, Crailsheim  
3.12.2 Freeware and databases 
Primer 3 from the Whitehead Institute for Biomedical Research; Cambridge, USA 
Genesis Version 1.7.5, Institute for Genomics and Bioinformatics; TU Graz, Austria 
Image Processing and Analysis in Java (ImageJ); NIH, USA 
David Bioinformatics database, Version 2007 (DAVID); NIAID, NIH, USA 
Kyoto Encyclopedia of Genes and Genomes (KEGG); University of Kyoto, Japan 
RMAExpress, V. 1.0 beta 10, Ben Bolstad, University of California, Berkeley, USA 
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4 Methods 
4.1 Microarray analysis 
4.1.1 ChipInspector analysis of CEL Files 
Transcription profiling using Affymetrix RG-U34A microarrays was performed on RNA 
from rat kidneys, described in 3.1 and 3.2.  
The microarray RG-U43A contained 93725 single probes with different sequences, 
control mismatch probes are not included. After the hybridization stage, the resulting 
fluorescent signals are translated into numeric data, the so called CEL files (see 3.1). 
Standard analysis of microarray data consists of a series of steps. Quality controls 
are used to detect degradation of the RNA input material. In a normalization step, the 
background signal levels are defined to allow comparisons between the different 
arrays. In the final step statistical analyses are used for evaluation of the significance 
of data.  
Due to problems of sensitivity and specificity of this analysis approach (for details see 
5.1., figure 12) the resultant CEL files were analyzed using the ChipInspector 
software [63]. 
The approach is based on single probes, avoids probe-set definitions, and each 
analysis is based on the most current single probe annotation. Mismatched probes or 
probes with known cross-hybridization are excluded from the analysis.  
Similar to the standard analysis this tool for microarray data that is comprised of four 
steps: single probe-transcript annotation, total intensity normalization, Significance 
Analysis of Microarrays (SAM) [64] (adapted to single probe handling), and transcript 
identification, based on significantly changed probes. All probes on the array were 
individually matched against the rat genome and all known transcripts thereof, 
available at the time of analysis. Only probes that matched uniquely to the genome 
and to at least one transcript (or overlapping transcripts) were retained for further 
analysis. SAM analysis was then carried out for each probe individually and the 
resulting probes showing significantly changed signals were then used to identify the 
corresponding transcripts (which may be more than one per gene). The expression 
ratios shown in the result table were calculated from the average expression levels of 
all significant probes of each individual transcript. Gene identifiers were then attached 
to each transcript. Analysis was carried out using all default settings,  
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as recommended by the software provider, except for the expected false discovery 
rate (FDR) which was set to maximal detection of regulated transcripts with lowest 
amount of falsely called features (FDR 0%). 
4.1.2 BiblioSphere and GO analysis  
A network of genes based on literature co-citations was built up using the 
BiblioSphere software (Genomatix Software GmbH, Munich, Germany). Based on 
these network, the distribution of differentially regulated genes was grouped 
according to functional, biological categories. The controlled hierarchical vocabulary 
of the Gene Ontology (GO) consortium provides a structured language applied to the 
functions of genes and proteins in all organisms (http://www.geneontology.org/) [65], 
and was used to subgroup them by gene ontology. 
4.1.3 Pathway analysis 
Pathways were identified using the DAVID bioinformatics database, Version 2007 
(DAVID) (http://david.abcc.ncifcrf.gov/) [66, 67] and the Kyoto Encyclopedia of Genes 
and Genomes (KEGG) databases (http://www.genome.jp/kegg/kegg2.html) [68-70]. 
Lists containing genes identified to be differentially regulated by the microarray can 
be uploaded to the DAVID database. In addition to GO categories, DAVID gives 
detailed information on every single gene regarding the different pathways it has 
been assigned to. Through a direct link to the KEGG, the database DAVID makes it 
possible to gain an overview of the roles of every single gene in different pathways. 
To analyze alterations in pathways, a version of the individual regulatory pathway 
was first defined by using the KEGG database. The initial KEGG-defined pathways 
were then refined to include additional target genes. Genes not yet annotated in the 
rat database were eliminated and additional points of potential interaction between 
various pathways were added. 
It was always taken into consideration that not every gene assigned to a pathway is 
necessarily available on the microarray employed. Therefore, the list of genes of 
interest, according to the pathway but not available on the array, could be obtained. 
Microarray data was integrated in schemes of adapted pathways to generate an 
overview of pathway activation and possible regulation. Primers were designed for 
genes, included in the arrays that showed regulation in a pathway of interest and for 
genes that were not present on the array for further analysis by qPCR. 
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4.1.4 Robust multichip average (RMA) analysis 
For the robust multichip average (RMA) analysis, the program RMAExpress Version 
1.0 beta 10 was used [71-74]. For each microarray, the manufacturer provides 
information about probe-set annotations on the array. This so called library file could 
be downloaded from the Affymetrix support webpage. In the first step of the analysis, 
the library file was loaded into the RMAExpress program. Only then could the CEL 
files of all the microarrays be loaded into the program, and be further processed. The 
analysis was computed automatically using default settings. A graphical output file in 
the form of boxplots could be generated to control for outliers between the arrays. A 
numeric output file (.txt format) contained expression values on a normal or a 
logarithmic scale, after the normalization. The .txt files could be used for further 
analysis.  
4.1.5 Cluster analysis 
Cluster analysis was performed using the program Genesis Version 1.7.5 [75]. This 
tool was developed to simultaneously visualize and analyze a whole set of gene 
expression experiments. After normalization with RMAExpress, the native text files 
were loaded as input into the Genesis program. The data of the individual arrays was 
log2 transformed and normalized by their genes. Hierarchical, average linkage 
clustering over genes and arrays was performed in order to show untainted, 
familiarity linkage. The graphical output was a matrix displaying clusters of co-
regulated genes and arrays. The information gained was twofold. First, an overview 
was gained of the general expression-patterns of genes from the individual animals. 
The more similar overall gene expression on the arrays, the closer the arrays of the 
individual animals would cluster together. The end stage of renal disease should 
cluster further away from the control kidneys. Second, genes with distinct expression 
patterns will cluster together, which gives an overview of the expression of individual 
genes or groups of genes and their expression patterns along with disease 
progression. A possible effect of the treatment on gene expression can easily be 
observed with this method and candidates for further evaluation can be chosen. 
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4.2 Verification of microarray results on the mRNA level 
4.2.1 RNA Cleanup 
RNA was isolated as described in 3.2.1. RNA cleanup was performed to remove 
residual contamination with genomic DNA. This procedure was performed with the 
reagents of the RNeasy Mini kit and according to the instructions of the RNeasy Mini 
Handbook 04/2006. The optional DNase I (Qiagen, Hilden, Germany) digestion step 
was included. RNA was eluted in 30 µl RNase free water. Elution was repeated once 
to maximize final RNA concentration.  
4.2.2 Quantification of RNA 
For quantification of RNA after cleanup, the Quant-iTTM RNA assay for the QubitTM 
fluorometer was employed. Quant-iT technology uses fluorescent dyes specifically for 
RNA. Upon binding to RNA, the fluorescence of the Quant-iT dyes increases several 
hundred fold, giving a very high signal-to-background ratio that is measured by the 
QubitTM fluorometer. This assay is highly selective for RNA. Measurements and 
calculations were performed according to the manufacturer’s protocol. 
4.2.3 Reverse Transcription 
The isolated total RNA was transcribed into cDNA through reverse transcription. The 
amount of cDNA was measured in a following qPCR reaction step. Primers designed 
for qPCR are usually cDNA specific, which means they will only amplify cDNA and 
not genomic DNA. For some genes, such as the S18-rRNA or genes consisting of 
just one exon it is not possible to design cDNA specific primers. For this reason, and 
to exclude a PCR signal from genomic DNA contamination in the sample, the so- 
called RT- sample was included into the reverse transcription step. Here, 0.1 µg of 
total RNA, possibly containing genomic DNA contamination, was added to the 
reaction batch. This batch equaled the RT+ batch with the exception of the reverse 
transcription enzyme. Since no reverse transcription could take place in this batch 
and RNA can not be measured in qPCR, each signal that was produced by the RT- 
had to originate from the combination of a cDNA unspecific primer and genomic DNA 
contamination. 
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RT PCR (1x)   
Reagent  RT+ RT-  
First-strand buffer (5x)           1x           1x 
dNTP        1.5 mM        1.5 mM 
DTT      13.4 mM      13.4 mM 
Rnasin        2.5 U/µl        2.5 U/µl
Acrylamid, linear        0.7 µM        0.7 µM 
Hexanucleotides (10x)        0.2x        0.2x 
Superscript II        4.4 U/µl - 
 
For the reverse transcription, 1.1 µg of total RNA, as measured in 4.2.2, was diluted 
in RNAse free water to a final volume of 33µl. Of that dilution, 30µl were added to the 
15 µl of the RT+ mastermix. The residual 3µl were diluted to 31µl with RNAse free 
water and added to the 14µl of the RT- mastermix. The RT+ mastermix therefore, 
contained 1 µg of RNA and the RT- mastermix contained 0.1 µg of RNA. Both 
reaction batches were incubated at 42°C, slowly shaken in a thermo block for 1.5 
hours. For subsequent qPCR reactions, the RT+ batch had to be diluted 1:10, 
whereas the RT- batch remained undiluted. Batches and dilutions were stored  
at -20°C, until further use. 
4.2.4 Quantitative PCR (qPCR) 
qPCR permitted to calculate the amount of amplification products in a specific PCR 
reaction. The qPCR is based on fluorescent signals generated through amplification 
of the sample and on the detection system’s laser technology that can measure 
fluorescence. There are two main concepts of qPCR, the Taqman assay and the 
SYBRgreen assay. In the case of the Taqman assay, primers and a double-labeled 
probe anneal to the cDNA. The probe is labeled with a fluorescent dye and a 
quencher. No fluorescent signal can be emitted, of a probe that is not bound to the 
cDNA and/or if the cDNA is not amplified. If primers and probe are bound to a 
specific cDNA and the Taq polymerase amplifies the strand, the 5’-3’- exonuclease 
activity of the polymerase will hydrolyze the probe and separate the fluorescent dye 
from the quencher. A fluorescent signal is then generated by the quencher free 
probe, labeled with FAM or VIC, which can then be measured by the detection 
system. 
In the case of the SYBRgreen primers, the fluorescent signal is generated by 
intercalation of the SYBRgreen dye in double stranded cDNA. To control that the 
Methods 
 33
signal did not originate from unspecific byproducts, an additional step had been 
included. After the amplification cycles, the PCR machine gradually increased the 
temperature up to 95°C. While doing so, the double strands generated through 
amplification separated again and the system could detect the loss of fluorescence. 
Each product had a melting temperature depending on its length. A melting curve 
could be displayed by the system. A single peak at a temperature that fited the size 
of the amplicon ensured that the product is specific. Both techniques were employed 
in this study. 
qPCR    
Reagent (1x) AoD QuantiTect Primer SYBRgreen Primer
Taqman Universal PCR Mastermix (10x) 1x - - 
SYBRgreen Mastermix (10x) - 1x 1x 
Taqman Assay (20x) 1x - - 
QuantiTect Primer - 1x - 
SYBRgreen Primer Fw - -    10 pM 
SYBRgreen Primer RV - -    10 pM 
Taq polymerase -      0.03 U/µl   0.03 U/µl 
 
H2O was added to the mastermix to reach a final volume of 18 µl. For qPCR 2 µl of 
the RT+ (1:10) dilution or 2 µl of the RT- reaction batch were added to the mastermix, 
to reach a final volume of 20 µl per well/taqman plate. Experiments were set up in 
duplicates. qPCR was performed on an ABIPrism7000 Sequence Detection system. 
After an initial hold of 2 minutes at 50°C and 10 minutes at 95°C, the samples were 
cycled 40 times at 95°C for 15 seconds, and 60°C for 60 seconds. All primers are 
summarized in the supplementary table 1. The expression of candidate genes was 
normalized to the reference gene 18S rRNA [76]. Primers were tested using pooled 
cDNA samples from each group of rats to identify significant differential regulation. If 
dysregulation in expression was observed between one or more groups, the qPCR 
was repeated using cDNA - samples from kidneys of individual animals. These 
results were then used for statistical analysis. 
4.2.5 Calculation of regulation 
The AbiPrism software detects fluorescence above a certain threshold, the so called 
Cycle Threshold (CT). A high CT indicates a detection of signal in a late cycle of the 
PCR which stands for low abundance of the mRNA in the original sample. The 
opposite is true for a low CT. 
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The CT is determined in the graphical output of the software after the PCR run. For 
each gene, a baseline was individually adjusted depending on the fluorescence 
curves. Using the log-scale view, the baseline for every gene was positioned within 
the area of the curve showing a linear increase. According to this baseline, a CT 
value was created by the software for every well of the PCR plate measured. 
Thereby, the CT represented expression values for the analyzed genes. To be able 
to analyze regulation of expression, fold changes (FCs) of the various experimental 
groups were calculated. Values of all the animal groups investigated were divided by 
the average value of the normal kidney, the control group. This means that all FCs, 
discussed in this work have to be regarded as changes in expression in relation to 
the expression level of the average normal kidney. 
FCs were generated using the Pfaffl method [77]. When the calculated FCs had 
values between 0 and 1, they were transformed according to the following formula 
[FC=-1*FC^(-1)] to achieve negativity of values. Thus, the distribution of expression 
values could be visualized on equal scales for up and downregulated genes in 
comparison to the control kidney. 
4.3 Verification of microarray and qPCR results on the protein level 
4.3.1 Histology 
Light microscopy evaluation was performed on 3 µm sections stained by periodic 
acid-Schiff (PAS). Kidneys were assessed for acute and chronic vascular, 
glomerular, as well as tubulointerstitial damage, as described [5]. 
Sirius red staining was used on sections to evaluate fibrotic changes in 
representative renal allografts [47]. Collagen forms the basic substance of connective 
tissue. It is composed of three amino-acids and stains strongly with acid red dyes due 
to the affinity of the cationic groups of the proteins for the anionic reactive groups of 
the acid dyes. By using the Sirius red staining total collagen could be evaluated in the 
sections to evaluate the overall fibrotic changes during CAD progression. PAS and 
Sirius red staining were performed by Ms. Gabrielle Schmidt, DKFZ, Heidelberg. 
4.3.2 Immunohistochemistry  
Immunohistochemistry (IHC) aims at localizing proteins in cells of a tissue section by 
specific antibody binding to antigens. Visualizing an antibody-antigen interaction can 
be accomplished in a number of ways.  
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In the most common instance, an antibody is conjugated to an enzyme, such as 
peroxidase, that can catalyze a color-producing reaction, ending with the local 
precipitation of a water-insoluble stain. Immunohistochemistry was performed on 
paraffin embedded formaldehyde-fixed tissue sections on glass slides, prepared as 
described in Adams et al. [5]. 
4.3.2.1 Sample preparation 
To remove the paraffin from the tissue, two washing steps, 10 minutes each, in xylol 
were performed. Rehydration of the sections was achieved by incubating them three 
times for 5 minutes in EtOH 100%, twice in EtOH 96%, once in EtOH 80% and once 
in EtOH 70%. To remove residual EtOH, one washing step with H2O followed. For 
unmasking of the antigen, sections were incubated in 0.01 M sodium citrate solution 
pH 6 or Tris buffer pH 9, in a steamer for 20 minutes approximately 70°C, or in a 
microwave for 1 hour at 98°C. Exact conditions for each antibody are reported below. 
The sections were then cooled down to room temperature and washed once in H2O. 
Depending on the antibody, an alternative unmasking step had to be performed. 
Thereby the sections were digested with protease XXIV solution for 10 minutes. 
Reaction was stopped by two washing steps in EtOH 100%. 
After antigen retrieval, sections were allowed to air dry and encircled with a liquid 
blocker pen to ensure that the small amounts of antibody solutions would remain on 
the tissue and not blend across the cover slide.  
4.3.2.2 Detection of the antigen 
Sections were rehydrated by two PBS/Tween washing steps. After rehydration, 
several blocking steps followed. All incubations were performed in a humid chamber, 
consisting of a metal box covered with wet pulp and a cover that ensured high 
humidity within the box and prevented the tissue from dehydrating during incubation 
periods. To prevent background reaction, it was necessary to block the endogenous 
peroxidase of the tissue. For this purpose, the sections were incubated in PBS 
containing 3% of hydrogen peroxide for 10 minutes. The sections were then washed 
twice with fresh PBS/Tween and blocked again with PBS containing 2% of blocking 
serum from the VECTASTAIN® Universal Quick kit for 10 minutes, followed again by 
two PBS/Tween washing steps. Before the antibody could be added endogenous 
biotin had to be blocked using the Avidin/Biotin Blocking Kit.  
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The general protocol for the antibody staining consisted of an incubation of the 
section with a primary antibody, followed by washing steps. Then, the secondary 
biotinylated antibody was incubated. All antibodies were prepared in antibody diluent 
(Dako). Concentrations of antibodies are summarized below.  
IHC    
Primary Antibody Retrieval Buffer  Dilutions 
Mouse anti-rat beta-catenin  Steamer Citrate 1/20 
Mouse anti-rat Cd44H Steamer Citrate 1/500 
Rabbit anti-rat collagen I Protease - 1/20 
Rabbit anti-human fibronectin Protease - 1/500 
Rabbit anti-rat Lef1 Microwave Tris 1/100 
 
All primary antibodies were incubated at room temperature for 2 hours. 
Incubation was followed by two PBS/Tween washing steps before the second 
biotinylated antibody, directed against the species of the primary antibody, was 
added for 30 minutes at room temperature. Concentrations were used as stated 
below. 
IHC  
Secondary Antibody Dilutions 
Biotinylated anti mouse  1/150 
Biotinylated anti rabbit  1/150 
 
The Avidin-Biotin-Complex method (ABComplex) was employed. Horse radish 
peroxidase (HRP) is complexed with streptavidin and conjugated to the biotinylated 
antibody. Sections were incubated for 60 minutes at room temperature in the ABC-
HRP solution. After incubation, the slides were washed twice with PBS/Tween and 
once with H2O. Then the slide was incubated using the AEC substrate kit for an initial 
3 minutes and the staining was controlled using light microscopy (Laborlux D, Leitz, 
Wetzlar). If necessary, the staining reaction could be prolonged for up to 10 minutes 
in total. The AEC subtrate was oxidized to a red stain. 
Before the counterstaining of the nuclei with Mayers Haemalaun, the slides were 
washed once with H2O. Slides were dipped for several seconds in Mayers 
Haemalaun and then incubated in tap water for about 10 minutes, resulting in a blue 
staining of the nuclei. A drop of mounting medium and a cover slide were added to 
protect the section. Slides were stored at room temperature, until investigated by 
microscopy. 
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4.4 Identification of the working mechanism of 13cRA on the DNA 
level 
4.4.1 Cell cultivation 
The adherently growing K4IM cells were cultured in DMEM medium in a cell culture 
incubator at 37°C, 100% humidity, and 5% CO2 until use. Before reaching confluent 
growth, cells were removed from the culture dish using Trypsin-EDTA. They were 
split and subcultured. For splitting, the culture medium was completely removed and 
cells were washed once with PBS. Trypsin-EDTA solution was added to just cover 
the cell layer. Cells were put back into the incubator until they started to detach. Then 
the reaction was stopped by the addition of an equal amount of culture medium 
containing serum. The cell suspension was softly pipetted up and down to ensure 
detachment of all cells. Then the suspension was transferred to a tube and 
centrifuged for 3 minutes at 1100 x g. The supernatant was discarded and the 
pelleted cells were resuspended in fresh culture medium and seeded on new culture 
plates. K4IM can be splitted up to 1:3. If necessary, cells were counted before 
splitting. 
4.4.1.1 Counting of viable cells 
Cells were counted using a Neubauer counting chamber. The cover slip had to be 
attached to the chamber in such a way so that the “Newton rings” were visible. Then 
the distance between chamber and slip is defined and the chamber could be used for 
counting. One part of the cell suspension was mixed with Trypan Blue solution in a 
1:1 ratio, staining dead cells blue. 10 µl of this mixture were immediately pipetted into 
the chamber. Only living cells were counted in all the quadrants of the chamber. The 
number of cells per ml suspension could then be calculated. The count (x) multiplied 
by the dilution and divided by the quadrants counted gave a number of x*104cell/ml 
cell suspension. 
4.4.1.2 Cryo-conservation of cells 
4.4.1.2.1 Freezing of cells 
The freezing medium was prepared by the addition of DMSO to culture medium in a 
concentration of 20%. After counting and centrifugation, cells were resuspended in 
the culture medium to reach a cell concentration of 1*106 cell/ml.  
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Cell suspension and freezing medium were now mixed 1:1 and immediately 
transferred in 2 ml aliquots into cryotubes. This led to 1*106 cells per cryotube and a 
final concentration of 10% DMSO in the freezing medium. The tubes were cooled 
down to -80°C over 24 to 48 hours and later on transferred to the gas-phase of a 
liquid nitrogen tank for long-term storage at approximately -130°C. 
4.4.1.2.2 Thawing of cells 
A cell culture plate with a warm culture medium was prepared. Frozen cells were 
thawed by dipping the cryotube into a 37°C waterbath until only the core of the 
suspension was frozen to indicate a temperature of 4°C within the cryotube. When 
this point was reached the suspension was immediately added to the prepared 
culture plate. On the next day, if adherent cells were attached to the plate and had 
time to recover, the whole culture medium and the residual DMSO were removed and 
replaced by a fresh culture medium. 
4.4.2 Cell culture and stimulation experiments 
Cells were cultured to 90% confluency on cell culture plates in culture medium. The 
medium was discarded and replaced by starving medium, followed by further 
incubation of the cells for 24 hours. After this, cells reached synchronization in the 
cellular cycle. K4IM were stimulated with TNFA and/or 13cRA, as established in our 
lab by Ana Belén, in batches of three conditions. All plates were supplied with freshly 
prepared medium according to the following table and incubated for 24 hours. 
Cell stimulation    
Medium and Reagents Control Stimulation Inhibition of Stimulation 
Starving medium + + + 
25 ng/ml TNFA  + + 
13cRA 10-5M     + 
 
After incubation, 2 ml of the supernatants were harvested and frozen at -20°C until 
they were analyzed by sandwich enzyme-linked immunosorbent assay (ELISA). Cells 
were further processed as described in 4.4.4. 
Methods 
 39
4.4.3 Enzyme-inked immunosorbent assay (ELISA) 
To ensure that stimulation of CCL5 production and the inhibition of this stimulation 
were successful, undiluted supernatants were tested for CCL5 production using the 
DuoSet ELISA Development kit, according to the manufacturer’s instructions. Optical 
density was determined using an ELISA reader GENiosPlus, set to 450 nm. 
The read-out was generated by the XFluor software. Calculation of results was 
performed using the Microsoft program Excel according to the manufacturer’s 
instructions. Only samples that showed a significant increase in CCL5 protein in the 
supernatants and a decrease after 13cRA stimulation were employed in ChIP 
analysis (data not shown). 
4.4.4 Chromatin immunoprecipitation (ChIP) 
The chromatin immunoprecipitation (ChIP) is a method used to determine the 
localization of protein of interest at a specific DNA binding site within the genome. 
This technique gives a picture of the protein-DNA interactions that occur inside the 
nucleus of living cells or tissues.This technique was used to investigate whether the 
nuclear co-repressor (NCOR) complex is bound to the CCL5 promoter under non-
stimulated conditions. If our hypothesis holds true, the NCOR should detach from the 
promoter after stimulation with TNFA but remain there, if the stimulation is inhibited 
by 13cRA. 
4.4.4.1 Chromatin preparation 
Cells were stimulated as described in 4.4.2. For the assessment of cell number one, 
an additional control plate was prepared. Samples were generated with 
approximately 2*106 cell/sample and condition. 
4.4.4.1.1 Formaldehyde fixation 
Formaldehyde was directly added to the medium to a final concentration of 1%. 
Samples were fixed at room temperature, gently shaken for ten minutes. The 
crosslinking reaction was stopped by adding glycine to a final concentration of  
125 mM and incubated for another 5 minutes.  
Cells were then washed twice with ice-cold PBS, containing 0.1% of a 50x protease 
inhibitor cocktail. Cells were scraped from the culture dish, transferred into 1.5 ml 
tubes, centrifuged and the supernatant was discarded. 
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4.4.4.1.2 Lysis of cells 
Cell pellets were resuspended in lysis buffer (600 µl/1*106cells) containing 0.1% of a 
50x protease inhibitor cocktail. After incubation on ice for ten minutes, the lysates 
were centrifuged at 2300 x g for 5 minutes at 4°C to pellet the nuclei. Subsequently, 
the nuclei were resuspended in 200 µl nuclei lysis buffer, containing 0.1% of a 50x 
protease inhibitor cocktail, and incubated on ice for ten minutes. At this step, samples 
can be frozen at -80°C. 
4.4.4.1.3 Sonication  
In order to fragment the DNA to an average length of 500 bp, the samples were 
exposed to ultrasound. To prevent the sample from being degraded by the 
developing heat and to prevent foaming, the individual samples were kept on ice 
during the whole sonication procedure. For sonication, the Sonifier250 was used, put 
to 20% duty cycle and set at level 2 for the output. Lysates were sonicated in four 
cycles at 20 pulses each with a 30 second interval between each round. To free 
samples of cell debris, they were centrifuged at 16000 x g for ten minutes at 4°C. The 
supernatants were transferred to fresh tubes and the pellets were discarded. 
4.4.4.1.4 Gel electrophoresis 
The correct size of the DNA fragments was controlled by running 1% of the sample 
on an agarose gel. Gel electrophoresis is a technique used for the separation of DNA 
using an electric current applied to an agarose gel matrix. A 2% agarose gel was 
prepared with a 0.5% TBE buffer. A solution of agarose was achieved by repeated 
heating of the mixture in the microwave. As soon as the agarose reached a 
temperature of approximately 50°C, it was cast onto the gel slide of the gel 
electrophoresis apparatus. After cooling, the solid agarose gel was placed in the 
running-chamber filled with 0.5% TBE. The sample augmented to 10 µl using H2O 
and mixed with 2 µl of loading buffer (6x) before being loaded on the gel. An 1kb size 
marker (Quick Load, NEB, Frankfurt) was applied to the first lane. A current of  
100 – 180 Volt was employed.  
After electrophoresis, the bands appearing in the gel were photographed using an 
UV-transilluminator connected to a gel documentation system (data not shown). 
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4.4.4.2 Immunoprecipitation 
4.4.4.2.1 Preparation of Pansorbin (StaphA) cells 
One gram of lyophylized Staphylococcus A (Pansorbin; StaphA) cells was 
resuspended in 10 ml of 1x dialysis buffer and centrifuged at 9300 x g for 5 minutes 
at 4°C. The supernatant was discarded. This washing step was repeated once. Then 
the cells were resuspended in 3 ml of 1x PBS plus 3% SDS and 10% BME. This 
mixture was boiled at 95°C for 30 minutes. After two more washing steps with 1x 
dialysis buffer, the cells were resuspended in 4 ml of 1x dialysis buffer, divided into 
50 µl aliquots, snap frozen and stored at -80°C till use. 
4.4.4.2.2 Blocking of Staphylococcus A cells 
An aliquot of frozen StaphA cells, sufficient to treat a sample originating of up to 
5*107 fibroblasts, was thawed. To prevent unspecific binding of StaphA cells to DNA 
or protein, 5 µl of herring sperm DNA and BSA, in concentrations of 10 mg/ml each, 
were added to the StaphA cells and incubated on a rotating platform at 4°C for at 
least 3 hours. Before use, the StaphA were washed three times with 1x dialysis buffer 
and finally resuspended in 50 µl of 1x dialysis buffer again. 
4.4.4.2.3 Preparation of samples 
The fibroblast samples, consisting of crosslinked and sheared chromatin fragments, 
dissolved in 200 µl nuclear lysis buffer were diluted 1:10 in the immuno precipitation 
(IP) dilution buffer to decrease the SDS concentration in the sample. The high SDS 
content would otherwise impede antibody binding. As total DNA input control, 1% of 
each sample was taken and frozen at -20°C. 
To preclear the samples, 5 µl of preblocked StaphA cells were added to each sample 
and incubated at 4°C for 15 minutes. The samples were then centrifuged at  
16000 x g at 4°C and the supernatants were transferred to fresh tubes. 
The following controls were included: a mock control consisting of IP dilution buffer 
instead of chromatin, a control containing no antibody and an isotype control for each 
condition. The aim was to check for DNA contaminations within the reagents in use 
and nonspecific interactions of the antibody. 
After sample and control preparation the antibody was added. The active chromatin 
and the NCOR antibody were whole serum antibodies. On inquiry, the manufacturers 
stated a concentration of 1 mg/ml (maximum). According to this information, of both 
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antibodies an estimated 2 µg per IP sample were used. Antibody and samples were 
incubated over night on a rotating platform at 4°C. 
4.4.4.2.4 Precipitation 
The over night incubation was followed by the precipitation of the antibody-immune 
complexes via the StaphA cells. 5 µl of preblocked StaphA cells were added to each 
sample and incubated on a rotating platform at 4°C for 15 minutes. This was followed 
by a centrifugation step at 16000 x g at 4°C and several washing steps. The washing 
procedure included two steps of 1x dialysis buffer and four steps of IP wash buffer. 
For each washing step, the pellet was dissolved in 600 µl of buffer. An additional 600 
µl of buffer was added and the samples were incubated on a rotating platform for 
three minutes, followed by centrifugation at 16000 x g at 4°C for 4 minutes. It is 
necessary to remove as much buffer as possible after each wash without aspirating 
the StaphA cell–antibody complexes. After the last wash, remaining traces of buffer 
had be completely removed. To separate the StaphA–Antibody–Protein-DNA 
complexes, the pellet was dissolved in 150 µl IP elution buffer containing SDS. The 
mix was shaken on a vortexer for at least 15 minutes and was then centrifuged. The 
supernatant, now containing only Protein - DNA complexes, was transferred to a 
fresh tube. This step was repeated once and eluted fractions were pooled. 
4.4.4.2.5 Decrosslinking and ethanol precipitation 
The aim of this step was to reverse the crosslinks generated through the 
formaldehyde fixation by heat and high salt concentration. Proteins bound to the DNA 
were denatured and thus, separated in this way from the DNA. The total DNA input 
controls (see 4.4.4.2.3) were thawed and diluted to a volume of 300 µl. NaCl at a final 
concentration of 0.3 M and 1 µl of RNase A (10 mg/ml) was applied to all samples. 
All samples were incubated for four hours or overnight at 65°C. After incubation, 2.5 
volumes of 100% EtOH were added to the samples to precipitate chromatin at -20°C 
overnight. 
4.4.4.2.6 Protease K digestion 
To ensure removal of most of the chromatin proteins from the sample, a protease K 
digestion was conducted. Samples were centrifuged at 16000 x g for 20 minutes at 
4°C. The ethanol was discarded, samples were centrifuged once again and residual 
ethanol removed completely. Pellets were allowed to air dry. Dried pellets were 
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dissolved in 100 µl of TE buffer. 25 µl of 5x PK buffer and 1.5 µl of protease K were 
added to each sample and incubated at 45°C for 1-2 hours in a heating block. 
4.4.4.3 DNA analysis 
4.4.4.3.1 Phenol-chloroform extraction 
In order to purify the DNA and remove residual RNA, protein or reagents, DNA was 
extracted once with phenol/chloroform/isoamyl alcohol and once with 
chloroform/isoamyl alcohol. To keep the loss of DNA as small as possible, the 
samples were diluted in TE buffer to a volume of 300 µl. One volume of Roti® – 
Phenol/C/I was added and samples were vortexed and centrifuged at 16000 x g for 3 
minutes. The upper aqueous phase containing the DNA was transferred to a fresh 
tube. One volume of chloroform/isoamyl alcohol was added to this sample, followed 
again by vortexing and centrifugation at 16000 x g for three minutes. The aqueous 
phase containing the DNA was transferred to a fresh tube and precipitated using 
EtOH 100%. 
4.4.4.3.2 Ethanol precipitation 
Sodium acetate was added to samples and total DNA input controls to a final 
concentration of 0.3 M. The expected amount of specific, enriched DNA in the eluted 
samples was marginal. Glycogen is an inert carrier, which is insoluble in ethanolic 
solutions and forms a precipitate that traps the target nucleic acid. 5 µl of that carrier 
were added to the samples. Finally, 2.5 volumes of ice cold 100% EtOH were added 
and all samples were precipitated over night at -20°C.  
After precipitation, samples were centrifuged at 16000 x g for 20 minutes at 4°C. The 
ethanol was discarded and samples were washed with one volume of 70% EtOH to 
remove residual salt that might influence the following PCR reaction. The samples 
were centrifuged once and residual ethanol was removed completely. Pellets were 
allowed to air dry completely. Dried pellets were dissolved in 30 µl of H2O. It was 
critical to ensure complete resuspension of DNA. This was achieved by repeated 
pipetting. Subsequently, the samples remained in a thermo block at 37°C for at least 
one hour. Repeated freeze and thaw cycles can be necessary to ensure complete 
dissolving of the DNA.  
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4.4.5 PCR analysis 
PCR analysis was employed as the last step to amplify the precipitated DNA. This 
was necessary in order to detect enrichment of specific DNA after precipitation. The 
DNA of interest can only be amplified by the specific primers of the PCR reaction, 
while the quantity of specific DNA was increased in contrast to the non specific DNA 
that could not completely be eliminated through the washing steps. Optimal 
conditions will produce strong signals in the samples compared to the controls. If a 
signal was detectable after the ChIP, it implied that the precipitated protein under 
investigation had bound to the DNA sequence under investigation at the moment of 
DNA fixation.  
PCR  
Reagent Batch 
ThermoPol buffer (10x)     1x 
NTPs (1.25 mM) 0.25 mM 
Forward 10pM   0.5 pM 
Reverse 10pM   0.5 pM 
Taq polymerase 0.25 U/µl 
 
H2O was added to reach a volume of 24 µl. For the PCR reaction, 1 µl of the 30 µl 
elution sample was added to a 24 µl PCR batch. PCR was performed on a Geneamp 
PCR system 9700PE. After an initial denaturing step of 5 minutes at 94°C, the 
samples were cycled 35 times, for 30 seconds at 94°C, followed by 60 seconds at 
65°C for annealing and 30 seconds at 72°C for elongation. All oligonucleotides are 
summarized in the supplementary table 1. 
4.5 Statistical analyses 
Statistical analyses were performed using Graph Pad Prism 4.03. For expression 
values of qPCR data, a non-parametric analysis of variance (ANOVA/ Kruskal–Wallis 
test) was performed to test for significant differences between the different groups of 
animals. Analysis of gene expression over time, compared to the control kidney was 
followed by the Dunn’s post test, correcting for multiple testing. Only the results of the 
post test are displayed. Effects of the treatment were followed by a Mann-Whitney-U 
Test. Only the results comparing the different groups at specific time points are 
displayed. P-values of less than 0.05 were considered to indicate statistically 
significant differences. 
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5 Results 
5.1 Transcriptomic profiling identifies progressive changes in the 
transplantation model during CAD 
CAD results of a complex set of processes that eventually manifests itself as a 
progressive fibrosing disease. While morphometric analysis can demonstrate 
progressive changes during CAD, the goal of this study was to characterize features 
at the transcriptomic level to help identify regulatory networks underlying the initiation 
and progression of tissue damage. 
A problem often associated with oligonucleotide-based Affymetrix DNA-microarrays 
is appropriate annotation of the probe-sets that are used to define a specific 
transcript. Regarding this, the annotation provided by the company of a significant 
number of probe-sets are not in line with our current knowledge of the genome as 
they might be based on data predating genomic sequencing [78, 79]. In addition, 
individual probes within the probe-sets can cross-hybridize with other transcripts 
leading to a skewing of data and an increase in false positive signals. Therefore, in 
addition to a standard analysis (data not shown), the recently developed 
ChipInspector software (Genomatix GmbH) was used for the analysis of the 
Affymetrix DNA microarrays, as described in 4.1. Both analyses yielded comparable 
numbers of regulated genes. The data outputs are represented by lists of compiled 
genes containing information about gene regulation and statistical significance. It has 
been previously demonstrated that this approach effectively reduces background 
noise and largely eliminates false positives in the analysis, thereby improving the 
sensitivity and specificity of the biological findings (data not shown and [63]). Figure 
12 displays similarities as well as differences of the two microarray analysis 
approaches. Transcriptomic profiling by microarray analysis demonstrated more than 
one thousand genes to be significantly regulated in the transplanted kidneys as 
compared to the control kidneys at the various time points tested (7 days, 14 days 
and 56 days after transplantation). The time points mark different stages observed in 
disease progression. The 7 day time point represents acute inflammation and by day 
14 this process begins to show chronic and fibrotic alterations. The 56 days time 
point represents severe chronic damage. 
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Fig. 12: Differences in microarray analyses. The diagram displays the basic steps of a microarray 
analysis and the difference between the standard and the ChipInspector (CI) analysis. The standard 
analysis is based on whole probe-sets, representing genes on the array. The single probe based CI-
analysis ignores probe-sets and regards single probes only. After hybridization, the CI performs an up-
to-date genome annotation check, for every single probe. Single probes, identified to be falsely 
assigned to a probe-set or to crosshybridize, are not evaluated for signal detection. Standard methods 
generate averages of fluorescence (F) intensity over all single probes of the probe-set. A signal is 
positive if the average overcomes a certain threshold (Th). In our example, this would result in a 
negative signal. In case of the CI, only verified single probes are taken into consideration for signal 
calculation which generates a positive signal, as in the example above. The advantage of the CI is 
fewer false positive or negative signals through up-to-date genome annotation of single probes. 
Figure 13 displays the workflow of the bioinformatical analysis and the programs 
employed.  
The lists compiled by the ChipInspector analysis include a gene identification number 
(GeneID) and a fold change relative to a specific time point. The lists were 
subsequently analyzed using BiblioSphere software from Genomatix GmbH. This 
software generates networks of genes connected by literature co-citations. The 
connection between genes can be graphically observed on different hierarchical 
levels. 
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Fig. 13: Bioinformatic analysis. The flowchart summarizes the single analyses performed and 
displays the workflow. After paralleling standard and CI analysis of CEL files, progressing analyses 
divide. CI (4.1.1) generated gene lists were loaded into BibloSphere (4.1.2) and DAVID (4.1.3) 
Standard microarray analysis results were normalized using RMAExpress (4.1.4) and subsequent 
hierarchical clustering was performed by the Genesis program (4.1.5). 
Due to the high numbers of genes, the standard BiblioSphere analysis was difficult to 
apply to our experimental data. However, an additional feature of the BiblioSphere 
software allows the categorization of genes according to the gene ontology (GO) 
consortium. 
The GO filter “biological process” was first employed to dissect and organize the 
gene lists. Over- or under-representation of genes assigned to a special GO group 
within the gene lists was automatically calculated and displayed by a “score”. This 
approach was used to identify groups of genes linked to specific biological 
processes.  GO groups with significant scores for over representation included 
“response to stress”, “response to stimulus” and several GO groups expected during 
tissue damage. No GO group regarding signal transduction showed a significant 
score. Further investigation was performed by applying the DAVID bioinformatics 
database tool. 
DAVID provides a comprehensive set of functional annotation tools that help provide 
a more detailed biological context behind large lists of genes. DAVID is linked to 
several databases that allow visualization of genes in pathway maps. These 
pathways were further studied in the context of gene expression associated with 
signal transduction by using the Kyoto Encyclopedia of Genes and Genomes (KEGG) 
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database of pathways. Using the functional annotation chart provided by the DAVID 
database, the association of individual genes with a regulatory pathway defined by 
KEGG was investigated. All the gene lists were uploaded and manually searched for 
pathway associations. Pathways associated with epithelial to mesenchymal transition 
(EMT, as described in 1.1.3) and fibrosis were evaluated in detail. These included 
NOTCH, TGFB, HH and WNT pathways. For each pathway, a list of genes, based on 
KEGG and recent literature was compiled. In many cases, genes playing critical roles 
in the different pathways were not present on the commercial microarray, which 
allowed no statement regarding their expression. Finally a list of genes for each 
pathway was generated for qPCR analysis that consisted of genes observed to be 
regulated according to the microarray analysis and critical genes not present on the 
array. 
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5.1.1 Inflammation associated gene expression in CAD 
Transplantation of a kidney initiates a series of complex pathophysiologic processes 
leading to the recruitment of immune effector cells to the graft. In the absence of 
sufficient immunosuppressive therapy and genetic match, this leads to persistent 
inflammation in the kidney tissue and chronic fibrotic damage.  
Transplantation of Fisher kidneys into Lewis rats without immunosuppression results 
in a smoldering inflammatory process. This activity has been linked to the 
development and progression of allograft dysfunction. In our animal transplantation 
model for CAD, an infiltrate consisting of monocytes/macrophages and CD8-positive 
T cells was demonstrated [5]. By morphometry, the inflammatory infiltrate was found 
to peak at early time points (7 to 14 days) and decrease towards the last time point 
(56 days).  
Transcriptomic profiling, combined with pathway modeling, was used here to 
characterize networks of genes that underlie the initiation and progression of CAD. 
The first set of genes examined, represented transcripts linked to inflammation.  
The genes investigated included the chemokine ligands 2, 3, 5 (Ccl2, Ccl3, Ccl5), 
interferon gamma (Ifng), interferon-inducible cytokine 10 (Cxcl10/Ip10), Tnfa, and the 
interleukins 1 beta and 6 (Il1b, Il6).  
With the exception of tumor necrosis factor alpha (Tnfa), the microarray analysis 
indicated strong upregulation of all investigated genes. qPCR verified that gene 
expression of these proinflammatory cytokines was upregulated at all tested time 
points as compared to a normal kidney. The mRNA expression of Ccl2, Ccl3, Ifng 
and Tnfa remained elevated after 7 days, whereas mRNA expression progressively 
increased for Ccl5 and Il6 after 14 and 56 days. Il1b and Cxcl10/Ip10 were rapidly 
upregulated to a peak on day 7 and then slowly declined. Results are summarized in 
figure 14. 
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Fig. 14: Inflammatory genes. Expression data of inflammation associated genes after qPCR 
analysis. Data was generated employing qPCR, as described in 4.2.4 and displayed fold changes 
were calculated, as described in 4.2.5. “Log” denotes a logarithmic scale, if not noted otherwise the 
scale is linear. For statistical analysis, the Kruskal-Wallis non-parametric test was applied to analyze 
the differences between the individual animal groups. Dunn’s post test was applied for multiple testing. 
Significant differences are denoted by an asterisk. * denotes a statistically significant difference with a 
p value < 0.05, ** denote a statistically significant difference with a p value < 0.01 and *** denote a 
statistically significant difference with a p value < 0.0001. 
Many of these proinflammatory cytokines have been previously shown to influence 
downstream signaling events. The activation of genes known to respond to 
inflammation-associated signal transduction was investigated.  
These included signal transducer and activator of transcription 1 (Stat1), interferon 
regulatory factor 1 (Irf1) and janus kinase 2 (Jak2), which are closely related with Ifng 
stimulated signal transduction. A minor but constant upregulation of Jak2 was 
observed. After ligand binding and receptor dimerization, JAKs dissociate from the 
receptor. This results in phosphorylation and dimerization of STATs which help to 
activate transcription of genes with specific response elements within their promoters.  
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The transcription factor Irf1 is one of these genes. Stat1 and Irf1 showed a strong 
upregulation, peaking on day 7 and decreasing afterwards. qPCR verified the 
upregulation of genes indicated by the microarray analysis. Other genes associated 
with inflammatory signal transduction included the toll-like receptor 4 (Tlr4), 
interleukin-1-receptor-associated kinase 3 (Irak3) and the nuclear receptor 
peroxisome proliferator activated receptor gamma (Pparg). IRAK3 acts as a 
downstream inhibitor of TLR4 signaling. Both genes showed a constant upregulation 
in transplanted kidneys. This expression suggests paralleled expression in certain 
cell types, such as monocytes/macrophages. Pparg showed highest upregulation on 
day 56. Figure 15 displays the genes assigned to inflammatory signal transduction. 
 
Fig. 15: Inflammation associated signal transduction. Expression data of genes assigned to 
signal transduction after qPCR analysis. Data was generated employing qPCR, as described in 4.2.4 
and displayed fold changes were calculated, as described in 4.2.5. For statistical analysis, the Kruskal-
Wallis non-parametric test was applied to analyze the differences between the individual animal 
groups. Dunn’s post test was applied for multiple testing. Significant differences are denoted by an 
asterisk. * denotes a statistically significant difference with a p value < 0.05, ** denote a statistically 
significant difference with a p value < 0.01 and *** denote a statistically significant difference with a p 
value < 0.0001. 
This analysis verified that acute inflammation as a reaction to the transplantation 
insult was reflected in altered gene expression. While inflammation is important to 
wound healing, persistent inflammation is thought to promote fibrosis and chronic 
tissue damage which leads to loss of organ function. 
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5.1.2 EMT and fibrosis associated gene expression in CAD 
Renal interstitial fibrosis is the hallmark of progressive kidney disease [80]. During 
fibrosis, extracellular matrix (ECM) is synthesized in excess by activated fibroblasts. 
Neither the origin of the activated fibroblasts nor the stimuli that lead to increased 
ECM production have been completely elucidated. Understanding the biological 
networks that regulate these processes is central to characterizing the underlying 
pathogenic events and may help to identify potential targets for therapeutic 
intervention. In pulmonary fibrosis, as well as in rodent kidney models, the epithelial-
to-mesenchymal transition (EMT) is presented as a potential mechanism of 
fibrogenesis during fibrosis in vivo [81, 82]. EMT is characterized by the de novo 
synthesis of alpha smooth muscle actin, upregulation of mesenchymal markers and 
the loss of E-cadherin. 
The expression of a series of marker genes linked to fibrosis and EMT were then 
evaluated in the progressive rat model by both array and qPCR analysis. 
Downregulation of E-cadherin (Cdh1) is associated with EMT. This is thought to allow 
the cells to acquire a motile phenotype [83]. Upregulation of the transcription factors 
connective tissue growth factor (Ctgf) and snail homolog 1 (Snai1) are thought to play 
a role in the downregulation of Cdh1 [17]. While steady state expression of all three 
genes was seen, no differential regulation of these genes was observed during the 
progression of tissue damage. Importantly, general markers of fibroblast activation 
and fibrosis including vimentin (Vim), smooth muscle actin (Actg2) and fibroblast 
specific protein 1 (Fsp1/S100a4) [7, 82] did show progressive upregulation by 
microarray and qPCR. 
To further characterize the induction and progression of fibrosis, mRNA expression of 
collagen type I (Col1a1) and collagen type III (Col3a1), pro-fibrogenic mediators such 
as tumor growth factor beta 1, 2, 3 (Tgfb1, 2, 3) and plasminogen activator inhibitor 1 
(Serpine1/Pai1) as well as the anti-fibrotic bone morphogenic protein 7 (Bmp7) was 
analyzed [8, 84, 85]. Both collagens were upregulated during disease progression. 
Tgfb2 and Tgfb3 showed no differential regulation. Tgfb1 expression was increased 
at all time points while Serpine1/Pai1 showed significantly increased expression only 
by day 56. Bmp7, a Tgfb1 antagonist, was coincidently downregulated with 
progression of CAD. Discussed in the context of EMT, BMP7 is able to counteract 
TGFB-associated renal fibrosis, and even reverse it [86-88]. 
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Fig. 16: Fibrosis associated genes. Expression data of fibrosis associated genes after qPCR 
analysis. Data was generated employing qPCR, as described in 4.2.4 and displayed fold changes 
were calculated, as described in 4.2.5. For statistical analysis, the Kruskal-Wallis non-parametric test 
was applied to analyze the differences between the individual animal groups. Dunn’s post test was 
applied for multiple testing. Significant differences are denoted by an asterisk. * denotes a statistically 
significant difference with a p-value < 0.05, ** denote a statistically significant difference with a p-value 
< 0.01 and *** denote a statistically significant difference with a p-value < 0.0001. 
Results of the analysis of profibrotic genes are summarized in figure 16. The 
upregulation of collagen mRNA was verified on the protein level using Sirius red 
staining which stains for total collagen and thereby shows the general level of fibrosis 
in a tissue sample. The results showed a progressive increase in collagen over time. 
Immunohistochemical staining for collagen I also showed increasing levels through 
all time points, as displayed in figure 17. 
Results 
 54 
 
Fig. 17: Sirius red and collagen I staining. Sirius red staining was performed on kidney sections 
by Ms. Gabrielle Schmidt from the DKFZ, Heidelberg, as described in 4.3.1. Collagen I staining was 
performed as described in 4.3.2. Figures display extracellular matrix deposition in rat kidney allografts 
on day 56 after transplantation (C,F) in comparison to allografts on day 7 after transplantation (B,E) 
and native Fisher rat kidneys (A,D). Sections are positive for Sirius red and collagen I (brown) staining 
in the tubulointerstitium, as well as in the subendothelial area of a preglomerular artery in the kidney 
allograft on day 56 after transplantation (C, F). (A-C: Sirius red; D-F: Immunostaining for collagen I 
(ABC method); 200x). 
After demonstrating the induction and progression of fibrosis in the rat model, the 
goal was then to characterize selective temporal changes in the pathways that are 
thought to be associated with fibrosis, EMT, and wound healing. Specifically, it was 
sought to characterize pathways that may help orchestrate the processes underlying 
fibrosis, and through this, identify potential targets for therapeutic intervention. 
5.1.3 Pathways regulated during progression of CAD 
Consistent with the hypothesis of a potential recapitulation of developmental 
programs after tissue injury, many pathways discussed in the context of fibrosis and 
EMT were originally identified during embryogenesis. By analyzing the temporal 
activation status of a series of these pathways during progressive tissue damage, the 
goal was to identify alterations in the networks of pathways responsible for the 
transition of inflammatory signals into profibrotic stimuli. It was hoped that by 
specifically focusing on crosstalk and alternative signaling between the distinct 
pathways, it might be possible to detect major switches and targets for therapeutic 
intervention. The pathways investigated included the NOTCH pathway, the TGFB 
pathway, the HH pathway, and the WNT signaling pathways. 
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Upregulation of the receptor Notch1 was indicated by the microarray analysis and the  
expression of Notch1 and the ligand jagged 1 (Jag1) was evaluated by qPCR. No 
differential regulation of the NOTCH pathway genes was observed via qPCR analysis 
suggesting that activation of this pathway could not be demonstrated in the context of 
our study. 
TGFB has been implicated as a master switch in the induction of fibrosis in many 
organs, and is a major mediator of EMT in a number of physiological contexts 
including tissue fibrosis [89]. Upregulation of Tgfb1 and the target gene Serpine/Pai1 
were observed. The main signaling pathway activated by TGFB1 acts through the 
SMAD proteins. The Smad genes were not present on the microarray and gene 
expression was assessed by qPCR. None of the investigated genes Smad1, Smad2, 
Smad3 and Smad4 demonstrated a significant change in expression during disease 
progression. It is known that TGFB1 can activate signal transduction in a SMAD-
independent manner. The ability of TGFB1 to crosstalk has been implicated for 
several pathways including RhoA, Ras, MAPK, PI3 kinase, NOTCH, and WNT 
signaling pathways [89]. 
5.1.3.1 Specific activation of the hedgehog pathway 
Binding of the hedgehog (HH) ligand to the receptor patched (PTCH1) leads to a 
relief of repression of the downstream receptor smoothened (SMO), followed by 
inhibition of transcription factor degradation and subsequent target gene expression. 
The mammalian HH homologues display intricate expression patterns during 
development, as well as in adult organisms [90]. HH signaling remains active in the 
adult where it is thought to help maintain tissue homeostasis [91]. HH has been 
recognized in different types of cancer [92], EMT [17, 93], stem cell biology, and 
tissue repair during chronic persistent inflammation [31]. The mRNA expression of 
HH pathway genes, according to the microarray analysis, is summarized in a 
schematic diagram of the alterations in the pathway during disease progression in 
figure 18. 
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Fig. 18: Microarray analysis of the hedgehog pathway. The scheme displays microarray data 
integrated into a modified version of the Hh pathway (discussed in 1.1.3.3). A white box marks a gene 
not annotated to the microarray. Boxes with an asterisk indicate further or additional investigation of 
the gene by qPCR. The sketch is divided in four parts displaying time points 0 (normal kidney), 7, 14 
and 56 days after transplantation. Triangles indicate the up or downregulation of genes in comparison 
to the control kidney. Red triangles indicate upregulation, green triangles indicate downregulation. 
Numbers displayed are ChipInspector generated fold changes. Displayed downstream target genes 
include Bmp4, Bmp7 and Ptch1. 
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Only a few HH genes including bone morphogenic proteins 4 and 7 (Bmp4,7), as well 
as the receptors patched 1 (Ptch1) and low-density lipoprotein related protein 2 
(Lrp2/Megalin) were present on the microarray, and showed differential regulation. To 
better characterize the activation of the HH pathway, genes assigned to this pathway 
were analyzed using qPCR. Analyses were performed for receptors Ptch1 and Lrp2, 
as well as the ligands sonic hedgehog (Shh), indian hedgehog (Ihh) and desert 
hedgehog (Dhh). Dhh is most closely related to the Drosophila hh, whereas Ihh and 
Shh are more closely related to each other, and represent a recent gene duplication 
[94].The three Hh genes are expressed in different tissues at different stages of 
development, suggesting different biological activities [95]. Expression of Ihh has 
been demonstrated in embryonic and adult kidney [96, 97]. Further, the expression of 
the HH-associated transcription factor Gli-kruppel member 1 (Gli1) and target genes 
secreted frizzled protein 1 (Sfrp1), Bmp4 and Bmp7 were investigated. The genes of 
the HH pathway showed very distinct expression patterns.  
The receptor Ptch1, a reliable indicator for HH signal reception, showed constant 
upregulation [95]. The receptor Lrp2 was strongly downregulated with tissue damage. 
This receptor is expressed on the apical site of the tubular epithelial cells and is 
thought to help establish the brush border of the kidney tubulus. The brush border is 
destroyed in the context of disease progression [5]. 
The HH ligands Ihh and Shh were downregulated, while Dhh demonstrated an 
increasing upregulation. The target genes Bmp4 and Bmp7 also showed a constant 
downregulation. The family of BMPs belongs to the superfamily of tumor growth 
factors and provides a connection between the HH pathway, TGFB signaling and 
fibrosis [98, 99]. The target gene Sfrp1 showed a minor upregulation that became 
statistically significant on day 14. It is linked to the WNT pathway, where it acts as an 
upstream pathway inhibitor [100]. qPCR results of the analysis of HH pathway 
regulation are summarized in figure 19. Supplementary table 2 summarized 
microarray results and gene names/symbols, displayed in figure 18. 
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Fig. 19: Hedgehog pathway associated genes. Expression data of hedgehog pathway associated 
genes after qPCR analysis. Data was generated employing qPCR, as described in 4.2.4 and displayed 
fold changes were calculated, as described in 4.2.5. For statistical analysis, the Kruskal-Wallis non-
parametric test was applied to analyze the differences between the individual animal groups. Dunn’s 
post test was applied for multiple testing. Significant differences are denoted by an asterisk. * denotes 
a statistically significant difference with a p-value < 0.05, ** denote a statistically significant difference 
with a p-value < 0.01 and *** denote a statistically significant difference with a p-value < 0.0001. 
These results demonstrate activation of a distinct part of the HH pathway. It seems 
that at least two sub-pathways exist, within the set of genes investigated. This might 
result from mixed culture effects. The ligand Dhh, together with the receptor Ptch1, 
the signaling molecule Gli1 and target genes such as Sfrp1, as well as several WNT 
pathway ligands (discussed in 5.1.3.2), are upregulated, demonstrating activation of 
this sub-pathway. In contrast, the ligands Shh and Ihh, together with the receptor 
Lrp2 and target genes such as the Bmps (discussed in 5.1.2) and again several, 
WNT pathway ligands are downregulated. 
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A close inter-relationship between HH and WNT pathways is evidenced by the fact 
that the WNT ligands are HH target genes. Crosstalk between the HH and the WNT 
pathway has been identified in embryonic development and cancer [101-103]. HH 
and WNT pathways regulate each other. An inhibitory relationship has been 
described in the context of epithelial cells of the colon and cancer [31, 104]. IHH has 
been directly addressed as WNT signaling inhibitor [104]. Having analyzed the role of 
HH pathway, the characteristics of the WNT pathways were further investigated. 
5.1.3.2 Specific and progressive changes of WNT genes and pathways  
Expression of WNT genes is regulated in a coordinated temporal and spatial manner 
during development [105]. WNT ligands are tightly associated with the extracellular 
matrix and tend to exert paracrine or endocrine, but not more distant effects [106]. 
Reactivation of WNT ligand expression and abnormal WNT signaling has been 
observed in an inflammatory, fibrotic diseases and cancer [40, 107-110]. 
The expression of individual WNT ligand genes was assessed by qPCR (only Wnt5a 
was present on the Affymetrix array and showed no regulation). Out of the 19 known 
Wnt genes, all but Wnt1 and Wnt16 were found to be expressed in rat kidney. 
However, Wnt3a, Wnt8a and Wnt10b were expressed at levels too low for us to 
reliably evaluate their regulation. Wnt3 showed a moderate upregulation. A 
statistically significant regulation was observed for Wnt2b, Wnt6, Wnt7a, Wnt7b, 
Wnt8b and Wnt10a. Wnt6 and Wnt7a expression were increased with CAD, while 
Wnt7b was downregulated – with the most pronounced effect seen on day 14. Wnt2b 
showed progressive downregulation during the development of CAD. Wnt8b and 
Wnt10a were also both downregulated relative to the normal control kidney. The 
Wnt8b downregluation was most pronounced on day 14 and Wnt10a on day 7. 
Results are summarized in table 1 and figure 20. 
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Fig. 20: Expression of Wnt genes. Expression data of Wnt ligands after qPCR analysis is 
displayed. Only Wnt5a was present on the array, therefore expression of all 19 Wnt ligands had to be 
evaluated by qPCR. Table 1 summarizes expression and regulation of all 19 Wnt ligands investigated. 
Data was generated employing qPCR, as described in 4.2.4 and displayed fold changes were 
calculated, as described in 4.2.5. For statistical analysis, the Kruskal-Wallis non-parametric test was 
applied to analyze the differences between the individual animal groups. Dunn’s post test was applied 
for multiple testing. Significant differences are denoted by an asterisk. * denotes a statistically 
significant difference with a p value < 0.05, ** denote a statistically significant difference with a p value 
< 0.01 and *** denote a statistically significant difference with a p value < 0.0001. 
WNT signaling may be directly activated through WNT ligand over-expression, or 
through alterations downstream in the WNT signaling cascade [111]. 
In the next step of our analysis, alterations in the different WNT signaling cascades, 
consisting of the canonical WNT, the WNT-Ca2+ and the WNT planar cell polarity 
pathway were investigated. 
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Table 1. Wnt gene expression and regulation in the rat kidney 
Gene ID Symbol Expression Signaling Regulation 
24881 Wnt1 not expressed in rat kidney Canonical  
114487 Wnt2 expressed Canonical n.s. 
116466 Wnt2b expressed ND Downregulation 
24882 Wnt3 expressed Canonical Upregulation 
303181 Wnt3b expression at detection limits Canonical could not be evaluated 
84426 Wnt4 expressed Wnt-Ca2+ n.s. 
64566 Wnt5a expressed WntCa2+ /PCP n.s. 
282582 Wnt5b expressed Wnt-Ca2+ n.s. 
316526 Wnt6 expressed Wnt-Ca2+ Upregulation 
114850 Wnt7a expressed Wnt-Ca2+ Upregulation 
315196 Wnt7b expressed Wnt-Ca2+ Downregulation 
291678 Wnt8a expression at detection limits Canonical could not be evaluated 
293990 Wnt8b expressed Canonical Downregulation 
287357 Wnt9a expressed ND n.s. 
303586 Wnt9b expressed ND n.s. 
316527 Wnt10a expressed Canonical Downregulation 
315294 Wnt10b expression at detection limits Canonical could not be evaluated 
140584 Wnt11 expressed Wnt-Ca2+/ PCP+ n.s. 
500047 Wnt16 not expressed in rat kidney ND  
Table 1: n.s. denotes a differential regulation not to be statistically significant. ND: not defined to 
activate a certain WNT signaling pathway. 
5.1.3.2.1 Regulation of the canonical WNT pathway 
Beta-catenin is the central regulator of the canonical WNT pathway. The protein is 
normally rapidly degraded. In WNT pathway activation, ligand binding to the frizzled 
receptor is followed by inhibition of beta-catenin degradation, allows nuclear beta-
catenin accumulation and subsequent effects on target gene transcription. General 
effects of canonical WNT pathway activation include proliferation, differentiation, and 
cell fate determination [108]. 
Transient upregulation of WNT beta-catenin signaling after tubular cell injury was 
described in vitro and in vivo [112, 113]. Analysis of microarray data allowed a 
schematic graph of the pathway and thus, importantly, a dynamic view of the 
components of the canonical WNT pathway that changed during the development of 
CAD as displayed in figure 21. Supplementary table 3 summarizes microarray 
results, gene names and symbols, displayed in figure 21. In addition, potential points 
of cross talk between the canonical WNT pathway with other regulatory pathways 
(e.g. HH, MAPK and TGFB) were added to the scheme. 
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Fig. 21: Microarray analysis of the Wnt canonical pathway. The scheme displays microarray 
data integrated into a modified version of the Wnt pathway (discussed in 1.1.3.4). A white box marks a 
gene not annotated to the microarray. Boxes with an asterisk indicate further or additional  
investigation of the gene by qPCR. The sketch is divided in four parts displaying time points 0 (normal 
kidney), 7, 14 and 56 days after transplantation. Triangles indicate the up or downregulation of genes 
in comparison to the control kidney. Red triangles indicate upregulation and green triangles indicate 
downregulation. The numbers displayed are ChipInspector generated fold changes (native scale, not 
log transformed). Displayed downstream target genes include Nos2, Cd44, Mmp7 and Fn1. 
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While beta-catenin was not found to be regulated at the mRNA level by microarray or 
qPCR analysis, nuclear accumulation of beta-catenin protein could be verified by 
immunohistochemistry. Control kidneys demonstrated a strong basolateral staining of 
epithelial cells of the tubule. During disease progression a shift from a predominantly 
basolateral to a cytoplasmatic localization and starting nuclear localization in 
endothelial cells was observed. Interestingly, expression was localized in nuclei 
preferentially in the endothelium of peritubular capillaries and in some tubular 
epithelia. This expression increased with fibrosis, as displayed in figure 22. 
 
Fig. 22: Beta-catenin nuclear localization. A: Control kidney, non-transplanted with strong 
basolateral positivity for beta-catenin in collecting ducts and distal tubules, staining in red. B: Kidney 7 
days after transplantation with a shift from a predominantly basolateral to a cytosolic localization and 
an increase in nuclear positivity in capillary endothelia (    ). Weak but clear cut label is detecable in 
nuclei of some epithelial-, and interstitial cells (>) (lower left). C: 14 days post transplantation pre-
collapsed tubules become noticeable in the kidney. Staining for nuclear beta-catenin in endothelial 
cells (     ) and with less pronounced nuclear label in some tubular epithelia (  ) can be demonstrated. 
D: 56 days after transplantation, there are many endothelial cells with nuclear positivity with different 
intensities (     : strong;  : weak). Collapsed tubules show strong beta-catenin positivity in epithelia, 
without clear distinction between cytoplasm and nucleus.(400x). 
The expression of genes assigned to the canonical WNT pathway by KEGG, showing 
differential regulation on the microarray, as well as pathway genes not included on 
the microarray, was further examined by qPCR over the course of the experiment.  
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The Wnt pathway genes investigated during CAD included the upstream Wnt 
pathway inhibitors secreted frizzled-related proteins 1, 4, 5 (Sfrp1,4,5), Wnt inhibitory 
factor 1 (Wif1) and Dickkopf homolog 3 (Dkk3). Additionally, gene expression of the 
WNT pathway genes glycogen synthase kinase 3 beta (Gsk3b), dishevelled 3 
(Dvl3_pred), Axin2, casein kinase 1 (Csnk1a1), transcription factors 1, 4, 5 (Tcf1, 4, 
5) and lymphoid enhancer binding factor 1 (Lef1) was examined. WNT pathway 
inhibitors showed no uniform expression pattern. No significant regulation of Sfrp4 
and Wif1 was observed. Sfrp1 and Dkk3, which is also a WNT target gene [100], 
showed a minor upregulation on day 14 and day 56, respectively. Sfrp5 showed an 
attenuated downregulation during all time points. Of the known WNT pathway genes, 
no differential expression was observed for Gsk3b, Dvl3_pred, Csnk1a1, Tcf4 and 5. 
However, a minor but not significant upregulation of Axin2 was observed on day 56. 
The canonical WNT pathway associated transcription factors Lef1 and Tcf1 displayed 
significant regulation during CAD. Lef1 upregulation was highest on day 7, but 
remained elevated throughout all the time points tested, while Tcf1 mRNA showed 
progressive downregulation in comparison to controls throughout all points, displayed 
in figure 23. 
 
Fig. 23: Expression of WNT canonical pathway genes Expression data of Wnt pathway genes 
after qPCR analysis is displayed. Data was generated employing qPCR, as described in 4.2.4 and 
displayed fold changes were calculated, as described in 4.2.5. For statistical analysis, the Kruskal-
Wallis non-parametric test was applied to analyze the differences between the individual animal 
groups. Dunn’s post test was applied for multiple testing. Significant differences are denoted by an 
asterisk. * denotes a statistically significant difference with a p value < 0.05, ** denote a statistically 
significant difference with a p value < 0.01 and *** denote a statistically significant difference with a p 
value < 0.0001. 
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These results suggest a progressive change in the pathway occurring during CAD 
with the initial changes seen by day 7 and pronounced changes evidenced by day 
56. The effect of these changes on the canonical WNT pathway can be evidenced by 
the expression of downstream target genes. Canonical WNT target genes 
investigated included fibronectin 1 (Fn1), Cd44 molecule (Cd44), matrix 
metalloproteinase 7 (Mmp7), nitric oxide synthase 2 (Nos2), myelocytomatosis 
oncogene (Myc) and bone morphogenic protein 4 (Bmp4) [110, 111, 114]. Fn1 and 
Cd44 showed upregulation over all points. Of all the genes investigated, Mmp7 and 
Nos2 were amongst the most drastically upregulated genes. The Myc gene, the first 
Wnt target gene to be identified [115], was found to be significantly upregulated on 
day 7 and expression remained elevated above normal kidney levels. Bmp4 was 
downregulated during progression of CAD, summarized in figure 24. 
 
Fig. 24: Expression of Wnt canonical target genes. Expression data of Wnt canonical target 
genes, after qPCR analysis. Data was generated employing qPCR, as described in 4.2.4 and 
displayed fold changes were calculated, as described in 4.2.5. “Log” denotes a logarithmic scale, if not 
noted otherwise the scale is linear. For statistical analysis, the Kruskal-Wallis non-parametric test was 
applied to analyze the differences between the individual animal groups. Dunn’s post test was applied 
for multiple testing. Significant differences are denoted by an asterisk. * denotes a statistically 
significant difference with a p value < 0.05, ** denote a statistically significant difference with a p value 
< 0.01 and *** denote a statistically significant difference with a p value < 0.0001. 
An increase in nuclear Lef1 within target cells could be demonstrated at the protein 
level (see figure 25), as well as the upregulation of Cd44 and fibronectin protein in 
the tubulointerstitial region was, by immunohistochemistry, using specific antibody 
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reagents. The general results observed closely paralleled those seen in the qPCR 
data, see figures 22 and 25. 
 
Fig. 25: Protein expression of the Wnt target genes. Lef1 (A-C), Cd44 (D-F) and fibronectin (G-I) 
in Fisher-Lewis rat kidney allografts. A: Control kidney non-transplanted: regular glomerular structure 
and typically differentiated tubules without nuclear Lef1 positivity, stained in blue. B: Kidney 7 days 
after transplantation with several interstitial mononuclear cells with strong Lef1 nuclear label. T: tubule; 
G: glomerulus. C: 56 days after transplantation kidney with collapsed tubule (T), ectatic capillary (Cap) 
and with nuclear Lef1 stain in mononuclear cells in the interstitium and focally in the tubule. (A-C, 
400x) D: Only a few Cd44+ cells can be observed in the native Fisher kidney; E: A high number of 
Cd44+ cells in the interstitium and glomeruli of kidney allografts were detected on day 7 as well as on 
day 56 (F) after transplantation; I: Tubulointerstitial fibrosis, transplant glomerulopathy and 
vasculopathy in rat kidney allografts on day 56 after transplantation are associated with strong 
expression of fibronectin, in comparison to acute rejection on day 7 after transplantation (H) or native 
Fisher rat kidneys (G). (Cd44: D-F; Fibronectin: G-I; 200x) 
These results suggest that WNT regulation and activation of the canonical WNT 
pathway occurs during progression of CAD. Strong upregulation could be 
demonstrated for most pathway genes, including transcription factors and target 
genes. Furthermore, the canonical WNT pathway displays downregulation of at least 
one transcription factor and one target gene, similar to the observation made in the 
regulation of the hedgehog pathway. 
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5.1.3.2.2 Changes in the WNT-Ca2+ pathway 
Following binding of WNTs to the frizzled receptors, WNT-Ca2+ pathway activation 
results in an increase in intracellular calcium. In contrast to the canonical WNT 
pathway, the downstream effects are beta-catenin independent. The WNT-Ca2+ 
pathway was shown to play a role in cell fate and morphogenesis [108]. 
The microarray analysis showed regulation of protein kinase C (Pkc), 
calcium/calmodulin-dependent protein kinase (Camk), protein phosphatase and 
phospholipase C (Plc), with progression of damage. All of these genes are 
associated with the WNT-Ca2+ pathway as displayed in figure 26. Supplementary 
table 4 summarizes microarray results and gene names/symbols, displayed in  
figure 26. 
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Fig. 26: Microarray analysis of the Wnt-Ca2+ pathway. The scheme is a modified version of the 
Wnt-Ca2+ pathway displayed on the KEGG database for rat (discussed in 1.1.3.4). A white box marks 
a gene not annotated to the microarray. Boxes with an asterisk indicate investigation of the gene by 
qPCR. The sketch is divided in four parts displaying time points 0 (normal kidney), 7, 14 and 56 days 
after transplantation. Triangles indicate the up or downregluation of genes in comparison to the control 
kidney. Numbers displayed are ChipInspector generated fold changes (native scale, not log 
transformed).  
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To study the activation status of this WNT pathway, mRNA expression of protein 
kinase C beta 1 and protein kinase C eta (Prkcb1, Prkch), calcium/calmodulin-
dependent protein kinase II beta and delta (Camk2b, Camk2d), protein phosphatase 
3, catalytic subunit, alpha isoform (Ppp3ca) and phospholipase C, beta 1 (Plcb1) was 
investigated by qPCR. Additionally, the expression of the transcription factors nuclear 
factor of activated T-cells 1, 2, 3, 4 and 5 (Nfatc1_pred, Nfatc2, Nfatc3, Nfatc4 and 
Nfat5) was determined, see figure 27. 
 
Fig. 27: Expression of Wnt-Ca2+genes. Expression data of Wnt-Ca2+ genes after qPCR analysis. 
Data was generated employing qPCR, as described in 4.2.4 and displayed fold changes were 
calculated, as described in 4.2.5. For statistical analysis, the Kruskal-Wallis non-parametric test was 
applied to analyze the differences between the individual animal groups. Dunn’s post test was applied 
for multiple testing. Significant differences are denoted by an asterisk. * denotes a statistically 
significant difference with a p value < 0.05, ** denote a statistically significant difference with a p value 
< 0.01 and *** denote a statistically significant difference with a p value < 0.0001. 
Prkcb1 and Prkch were found to be strongly increased with CAD. Ppp3ca, Plcb1 and 
Camk2d regulation at the mRNA level could not be confirmed, but upregulation of 
Camk2b was seen on day 56. While Nfatc3, Nfatc4 and Nfat5 showed no differential 
regulation, expression of Nfatc1_pred and Nfatc2 was progressively increased over 
time. Supplementary tables 3 and 4 summarize the expression data from the 
microarrays, and genes verified by qPCR for Wnt canonical and Wnt-Ca2+ pathways.  
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5.1.3.2.3 The WNT planar cell polarity pathway 
The Wnt planar cell polarity pathway is associated with cell movement, 
morphogenesis and metastasis [108]. As in the WNT-Ca2+ pathway, signals are 
transduced without the involvement of beta-catenin. 
The regulation of genes linked to the WNT-associated planar cell polarity pathway, 
include mitogen-activated protein kinase 9 (Mapk9), Rho-associated, coiled-coil 
containing protein kinase 1 (Rock1), and dishevelled 3 predicted (Dvl3_pred). While 
each of these genes was found to be expressed in normal rat kidney, none showed 
regulation of basal mRNA expression in the context of progressive tissue damage in 
our model. In summary, these results demonstrate a reflection of inflammation and 
fibrosis in the transcription. No direct indication of the involvement of EMT during 
progression of CAD could be demonstrated in our animal model. Regarding the 
pathways analyzed, regulation of the HH and various WNT signal transduction 
pathways was identified. 
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5.2 13cRA is a master regulator of CAD induced transcriptomic 
alterations 
5.2.1 Cluster analysis of overall gene expression 
A direct effect of 13cRA treatment on the development of CAD in this model was 
previously demonstrated [5]. Animals treated with 13cRA showed excellent 
preservation of renal function and statistically significant reduced fibrosis. The 
transcriptomic profiling results of animals treated with 13cRA were compared and 
contrasted with the results of the placebo treated animals, as discussed in 5.1. 
Interestingly, despite the histological findings showing good preservation of kidney 
morphology by 13cRA treatment, transcriptomic profiling of these largely “normal” 
tissues still showed a dramatic regulation of genes as compared to the control 
kidneys.  
Employing hierarchical clustering with euclidean distance on all arrays, a grouping of 
the normal kidneys together with the treatment group on day 56 could be observed. 
The linkage of the normal kidney group with the 56 days treatment group is in 
contrast to the other time points and the 56 day placebo group, whose branching 
shows the largest distance, as seen in figure 28. 
 
Fig. 28: Clustering of samples. Employing the Genesis program (see 4.1.5) to expression data, 
normalized by RMAExpress (see 4.1.4), the upper part of the figure displays unprocessed data and 
the order of all 30 arrays (upper row starting with N_0_3), as loaded into the program. After 
hierarchical clustering, the sequence of arrays changed. On the right side of the tree, the three normal 
kidney controls cluster in close proximity to the 56 day treatment group arrays. 
Although the day 56 treatment group showed similarities to non-grafted organs, a 
lack of concordance of the gene-expression profiles is apparent. Differences in 
expression are expected, due to an infiltrate in the transplanted organs that is not 
present in the control kidneys. Nevertheless, the allografts from the treated animals 
appear to have an overall gene-expression profile resembling that of normal kidneys. 
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Figure 29 demonstrates in two exemplary clusters how well the control group and the 
56 days treatment group are distinguishable from the other groups in their expression 
pattern. 
 
Fig. 29: Clustering of genes Employing the Genesis program (see 4.1.5) to expression data, 
normalized by RMAExpress (see 4.1.4). The diagram displays expression data after hierarchical 
clustering. Both exemplary clusters demonstrate uniform expression patterns of the normal, control 
kidney arrays and 56 days treatment arrays, in contrast to the other experimental groups. The red 
color indicates relative upregulation of genes and the green color indicates downregulation of genes, 
in comparison to the average expression level. 
This observation reflects the changes observed in histology after treatment with 
13cRA for the period of 56 days [5].  
The goal of the second part of the study was to identify potential therapeutic 
mechanisms of 13cRA function by analysis of potential alterations in the regulatory 
pathways linked to disease progression identified earlier (5.1.3.1 and 5.1.3.2). 
As in the first part of the study, the expression values of all time points of the 
treatment group were compared to the control kidneys serving as time point zero. For 
the second part of the analysis, these differences in gene expression were then 
compared, between the placebo and treatment group and contrasted for each time 
point. 
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5.2.2 The retinoic acid – HH – WNT axis 
Retinoic acid (RA) has complex and pleiotropic functions during vertebrate 
development [116]. RA is recognized as an important signaling molecule, which can 
influence developmental pathways including hedgehog [116]. In vitro SHH and RA 
exert synergistic effects on the differentiation of mesenchymal stem cells [117]. 
A link between retinoids or members of the steroid family with the WNT pathway is 
well defined [111]. Nuclear receptors including PPARG and the RAR receptor bind 
beta-catenin and/or regulate activation of WNT target genes [118]. RAR can form a 
complex with beta-catenin competing with TCF/LEF1 for the binding to the DNA, thus 
suppressing its activity [111] (the inhibitory relation between the HH and WNT 
pathway has already been addressed in 5.1.3.1). 
5.2.2.1 HH pathway 
Genes associated with the HH pathway underwent changes during CAD (5.1.3.1) 
and treatment with 13cRA modulated expression of genes assigned to this pathway. 
The results from microarrays of the treatment group were integrated into the 
schematic diagram of the pathway and are displayed in supplementary figure 1. 
Comparing microarray results of the placebo and treatment groups revealed 
increased numbers of genes to be regulated in both groups. In addition, qPCR was 
performed for Ptch1, Lrp2, Shh, Ihh, Dhh, Gli1, Bmp4, Bmp7 and Sfrp1. 
The receptor Ptch1 demonstrated an attenuated upregulation in the treatment group 
which was significant by day 56. The downregulation of the receptor Lrp2 seen 
during CAD could be prevented by 13cRA treatment, returning its expression close to 
that seen in normal kidneys on day 56. 
13cRA treatment resulted in modulation of mRNA expression of the HH ligands Ihh, 
Shh and Dhh on day 56. In the case of Ihh, the expression pattern was almost 
identical to that seen with Lrp2 expression. The downregulation of Ihh, Shh and Lrp2 
observed during CAD could be prevented by 13cRA treatment. No effects were 
observed on the expression of the transcription factor Gli1. The downregulation of 
Bmp4 and Bmp7 was limited, and the difference between placebo and treatment 
group became significant on day 56 for Bmp7. The target gene Sfrp1, upregulated in 
the placebo group, was significantly downregulated during all time points in the 
treatment groups (figure 30). The 13cRA treatment was found to reverse many of the 
Results 
 74 
progressive changes seen in the HH pathway during CAD and potentially to induce a 
switch in sub-pathway regulation. 
 
Fig. 30: Expression of hedgehog pathway genes. Through qPCR, expression of genes was 
assessed for all experimental groups. “C” denoting the Placebo/ untreated control group and “T” 
denoting the Treatment/13cRA group. Data was generated employing qPCR, as described in 4.2.4 
and displayed fold changes were calculated, as described in 4.2.5. “Log” denotes a logarithmic scale, 
if not noted otherwise the scale is linear. For statistical analysis, the Mann-Whitney-U non-parametric 
test was applied to analyze the differences between the placebo and treatment groups, comparing 
individual time points. Significant differences are denoted by an asterisk. * denotes a statistically 
significant difference with a p value < 0.05, ** denote a statistically significant difference with a p  
value < 0.01. 
5.2.2.2 WNT pathway 
The WNTs are target genes of the HH pathway. Analysis of the CAD transcriptome 
showed the modulation of expression of seven Wnt genes in our rat model. 
Treatment with 13cRA exerted significant effects on the expression of Wnt2b, Wnt3, 
Wnt6, Wnt8b and Wnt10a. The downregulation of gene expression for Wnt2b and 
Wnt10a was attenuated. qPCR detected that downregulation of Wnt7b and Wnt8b 
was even more pronounced than in the placebo group. While Wnt3 and Wnt7a 
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showed an attenuated upregulation, Wnt6 demonstrated a significant upregulation on 
days 7 and 14 and a significant downregulation compared to the placebo group, see 
figure 31. 
 
Fig. 31: Expression of Wnt ligands. Through qPCR, expression of genes was assessed for all 
experimental groups. “C” denoting the Placebo/ untreated control group and “T” denoting the 
Treatment/13cRA group. Data was generated employing qPCR, as described in 4.2.4 and displayed 
fold changes were calculated, as described in 4.2.5. “Log” denotes a logarithmic scale, if not noted 
otherwise the scale is linear. For statistical analysis, the Mann-Whitney-U non-parametric test was 
applied to analyze the differences between the placebo and treatment groups, comparing individual 
time points. Significant differences are denoted by an asterisk. * denotes a statistically significant 
difference with a p value < 0.05, ** denote a statistically significant difference with a p value < 0.01. 
Along with disease progression, the microarray analysis of the WNT canonical 
pathway revealed regulation of increasing numbers of pathway genes, in both 
experimental groups. Supplementary table 3 and figure 2 summarize the results and 
display the microarray results for the WNT pathway, visually comparing data of the 
placebo group to data of the treatment group, for each time point of the analysis  
qPCR revealed a significant difference in the expression of most genes of this 
pathway investigated on day 56 after transplantation. The HH target gene and WNT 
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inhibitor Sfrp1, upregulated in the placebo group, was downregulated in the treatment 
group (5.2.2.1). 13cRA treatment had no effect on the inhibitor Sfrp5 and caused a 
significant downregulation of the inhibitor Dkk3, which is also a WNT target gene. 
Axin2 was downregulated compared to control kidney on days 7 and 56. The 
transcription factors Lef1 and Tcf1 showed attenuation of the up and downregulation, 
respectively seen in progressive CAD. All target genes, with the exception of Bmp4, 
showed significant differences in the mRNA levels between the placebo and the 
treatment group on day 56 after transplantation. On day 56 the previously elevated 
levels of Cd44 and Fn1 were found to return to control kidney levels, as did Myc 
levels. Interestingly, while the mRNA levels of Nos2 and Mmp7 remained elevated 
above normal kidney levels, they were significantly decreased on day 56, in 
comparison to the placebo group. Results are summarized in figure 32 and 33. 
 
Fig. 32: Expression of Wnt canonical pathway genes. Trough qPCR, expression of genes was 
assessed for all experimental groups. “C” denoting the Placebo/ untreated control group and “T” 
denoting the Treatment/13cRA group. Data was generated employing qPCR, as described in 4.2.4 
and displayed fold changes were calculated, as described in 4.2.5. “Log” denotes a logarithmic scale, 
if not noted otherwise the scale is linear. For statistical analysis, the Mann-Whitney-U non-parametric 
test was applied to analyze the differences between the placebo and treatment groups, comparing 
individual time points. Significant differences are denoted by an asterisk. * denotes a statistically 
significant difference with a p value < 0.05, ** denote a statistically significant difference  
with a p value < 0.01. 
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Fig. 33: Expression of Wnt canonical target genes. Through qPCR, expression of genes was 
assessed for all experimental groups. “C” denoting the Placebo/ untreated control group and “T” 
denoting the Treatment/13cRA group. Data was generated employing qPCR, as described in 4.2.4 
and displayed fold changes were calculated, as described in 4.2.5. “Log” denotes a logarithmic scale, 
if not noted otherwise the scale is linear. For statistical analysis, the Mann-Whitney-U non-parametric 
test was applied to analyze the differences between the placebo and treatment groups, comparing 
individual time points. Significant differences are denoted by an asterisk. * denotes a statistically 
significant difference with a p value < 0.05, ** denote a statistically significant difference  
with a p value < 0.01. 
In the WNT-Ca2+ pathway, alterations in gene expression could be observed by 
microarray analysis. Supplementary figure 3 summarizes alterations observed over 
time, and compares the microarray results of the placebo and to that of the treatment 
groups. 
By qPCR analysis, no effect was observed on the expression of Camk2b, following 
13cRA treatment. However, all other genes investigated in this context showed 
reduced upregulation on day 56 through treatment. Differences in expression levels 
were found to be significant for Prkcb1, Prkch1, Nfat1_pred and Nfat2, as 
summarized in figure 34. No differential gene regulation was observed either with or 
without 13cRA treatment in the WNT-PCP pathway (data not shown). 
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Fig. 34: Expression of Wnt-Ca2+ pathway genes. Through qPCR, expression of genes was 
assessed for all experimental groups. “C” denoting the Placebo/ untreated control group and “T” 
denoting the Treatment/13cRA group. Data was generated employing qPCR, as described in 4.2.4 
and displayed fold changes were calculated, as described in 4.2.5. “Log” denotes a logarithmic scale, 
if not noted otherwise the scale is linear. For statistical analysis, the Mann-Whitney-U non-parametric 
test was applied to analyze the differences between the placebo and treatment groups, comparing 
individual time points. Significant differences are denoted by an asterisk. * denotes a statistically 
significant difference with a p value < 0.05, ** denote a statistically significant difference  
with a p value < 0.01. 
Taken together, the results suggest that 13cRA may act as a regulator of HH and 
WNT signaling and that these effects may help explain the therapeutic effects seen 
during renal allograft damage.  
In addition to the specific effects on these pathways, potential effects of 13cRA 
treatment, on the general immune and micro-milieu within the treated kidneys, were 
further investigated. 
5.2.3 13cRA influences the proinflammatory and profibrotic milieu 
Retinoids can have anti-inflammatory as well as anti-proliferative effects in diverse 
biologic systems [52]. The oral treatment of the rats with 13cRA within this study 
would have systemic effects, as well as local effects. Alterations in the inflammatory 
and profibrotic milieu observed in the kidneys after transplantation could help limit 
damage and preserve organ structure and function. Treatment with 13cRA 
decreased mRNA levels of almost all the inflammatory genes investigated. With the 
exception of Jak2, 13cRA had a significant effect on the expression of all genes 
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analyzed, during at least one point. Figures 35 and 36 summarize the results of the 
effect of 13cRA on inflammation-associated genes. 
 
Fig. 35: Expression of inflammation associated genes. Through qPCR, expression of genes was 
assessed for all experimental groups. “C” denoting the Placebo/ untreated control group and “T” 
denoting the Treatment/13cRA group. Data was generated employing qPCR, as described in 4.2.4 
and displayed fold changes were calculated, as described in 4.2.5. “Log” denotes a logarithmic scale, 
if not noted otherwise the scale is linear. For statistical analysis, the Mann-Whitney-U non-parametric 
test was applied to analyze the differences between the placebo and treatment groups, comparing 
individual time points. Significant differences are denoted by an asterisk. * denotes a statistically 
significant difference with a p value < 0.05, ** denote a statistically significant difference  
with a p value < 0.01. 
Results 
 80 
 
Fig. 36: Expression of inflammatory signal transduction associated genes. Through qPCR, 
expression of genes was assessed for all experimental groups. “C” denoting the Placebo/ untreated 
control group and “T” denoting the Treatment/13cRA group. Data was generated employing qPCR, as 
described in 4.2.4 and displayed fold changes were calculated, as described in 4.2.5. “Log” denotes a 
logarithmic scale, if not noted otherwise the scale is linear. For statistical analysis, the Mann-Whitney-
U non-parametric test was applied to analyze the differences between the placebo and treatment 
groups, comparing individual time points. Significant differences are denoted by an asterisk. * denotes 
a statistically significant difference with a p value < 0.05, ** denote a statistically significant difference 
with a p value < 0.01. 
A potential regulatory role of retinoic acid in immune tolerance and development of 
regulatory T cells has been proposed [119-121]. The expression of marker genes 
associated with different T cell populations was investigated to analyze possible 
effects of 13cRA treatment on the T cell and immune milieu. These markers included 
Foxp3, Il10, interleukin 4 receptor (Il4r), interleukin 6 receptor (Il6r), Il17, Il21 and 
interleukin 23 (Il23). Neither during disease progression, nor in the treatment groups 
was a change in expression of IL23 or IL17 detectable (data not shown). On day 7, 
the Foxp3 expression level of the placebo group equaled that of the treatment group. 
On day 14, Foxp3 was more upregulated in the treatment group and on day 56 it was 
downregulated. Il10 and Tgfb1 were upregulated. Il21 was most strongly upregulated 
in the non-treated group on day 7. The Il6r and its ligand Il6 were upregulated in the 
placebo group. This upregulation was significantly reduced for Il6 by 13cRA 
treatment on day 56. Il4r showed only minor upregulation at all time points - with no 
significant differences in expression seen following treatment. This suggests that 
even though a milieu that could stimulate the generation of Th17 cells is present in 
the kidney, no upregulation of Il17 on the gene expression level was observed. The 
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presence of cells expressing Foxp3, in the kidneys investigated was observed. A 
stimulatory effect of retinoic acid on the Foxp3 expression could not be 
demonstrated. Results are summarized in figure 37. 
 
Fig. 37: Expression of genes associated with a T cell development. Through qPCR, expression 
of genes was assessed for all experimental groups. “C” denoting the Placebo/ untreated control group 
and “T” denoting the Treatment/13cRA group. Data was generated employing qPCR, as described in 
4.2.4 and displayed fold changes were calculated, as described in 4.2.5. “Log” denotes a logarithmic 
scale, if not noted otherwise the scale is linear. For statistical analysis, the Mann-Whitney-U non-
parametric test was applied to analyze the differences between the placebo and treatment groups, 
comparing individual time points. Significant differences are denoted by an asterisk. * denotes a 
statistically significant difference with a p value < 0.05, ** denote a statistically significant difference 
with a p value < 0.01. 
Morphometric analysis of kidneys showed inhibition of subendothelial fibrosis in 
13cRA treated animals [5]. This was reflected in the transcriptomic studies where 
13cRA treated animals showed reduced upregulation of markers of fibroblast 
activation including Vim, Actg2 and Fsp1/S100a4. Similar effects were observed for 
Col1a1 and Col3a1 following treatment (figure 38). 
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The effect of 13cRA treatment was significant with respect to elevated Tgfb1 levels 
on day 56.  
The TGFB1 target gene Serpine1/Pai, which was increased at late stages of CAD, 
was not increased following treatment, suggesting a direct effect on the TGFB1 
pathway. The TGFB1 antagonist Bmp7 showed less pronounced downregulation 
during treatment as compared to the placebo-treated animals.  
 
Fig. 38: Expression of marker genes of fibrosis. Through qPCR, expression of genes was 
assessed for all experimental groups. “C” denoting the Placebo/ untreated control group and “T” 
denoting the Treatment/13cRA group. Data was generated employing qPCR, as described in 4.2.4 
and displayed fold changes were calculated, as described in 4.2.5. “Log” denotes a logarithmic scale, 
if not noted otherwise the scale is linear. For statistical analysis, the Mann-Whitney-U non-parametric 
test was applied to analyze the differences between the placebo and treatment groups, comparing 
individual time points. Significant differences are denoted by an asterisk. * denotes a statistically 
significant difference with a p value < 0.05, ** denote a statistically significant difference with a  
p value < 0.01. 
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Figure 40 summarizes the alterations in gene expression observed during disease 
progression or after 13cRA treatment focusing on the roles of the HH and the WNT 
canonical pathways. Transcriptomic profiling revealed changes in gene expression 
levels of genes associated with inflammation and fibrosis during progression of CAD.  
5.2.4 Working mechanism of 13cRA at the promoter level 
5.2.4.1 13cRA mediates inhibition of TNFA stimulated CCL5 promoter 
activation 
The potential working mechanism of 13cRA was previously investigated at the 
promoter level. TNFA-induced activation of the exemplary gene - CCL5, is inhibited 
by 13cRA. Promoter analysis suggested that the effect of 13cRA did not appear to be 
mediated through direct binding of RXR/RAR complexes to the CCL5 promoter, since 
deletion of the relevant consensus sequences did not influence 13cRA suppression 
of CCL5 promoter activity [5]. The results suggested an indirect effect of 13cRA, 
potentially acting through other transcriptional regulators. To this end, modulation of 
binding of the nuclear corepressor (NCOR) to the CCL5 promoter was investigated 
as a potential mode of action of 13cRA. 
5.2.4.2 Nuclear corepressor (NCOR) binding to promoters  
Chromatin immunoprecipitation (ChIP) experiments were performed to investigate 
whether 13cRA utilizes the same mechanism for the transrepression of CCL5 
promoter activation as identified by Pascual et al. [59] for a PPARG-dependent 
repression of the Nos2 promoter. If this mechanism was also active in the control of 
CCL5 transcription by 13cRA, then binding of the NCOR to the CCL5 promoter under 
non- stimulated or transrepressed conditions should be observed. 
5.2.4.2.1 Establishing the ChIP 
Chromatin immunoprecipitation was tested and a protocol established in our lab. 
Formaldehyde fixation is critical for later detection of protein binding sites on the 
chromatin. Formaldehyde concentrations in the range of 0.5% to 2% formaldehyde 
have been tested. Fixation using 0.5% led to problems with immune precipitation, the 
fixation with 2% formaldehyde was found to inhibit the lysis of cells and nuclei, and 
thereby to limit access of the antibody to the target proteins. A concentration of 1% 
appeared to be appropriate and was employed for subsequent experiments. After 
fixation, shearing of the chromatin is the next step of the protocol which is a critical 
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issue for the specificity of these experiments. Shearing conditions were found to 
depend on the volume of the sample, the origin of the chromatin and the total amount 
of chromatin. Extended sonication resulted in foaming, overheating and denaturation 
of the chromatin, and therefore loss of the sample. Insufficient shearing produced 
chromatin fragments that were too large for the examined DNA binding protein to be 
assigned to a specific promoter region. Sonication of chromatin was optimized to 
render an average fragment length of 500 bp [122], within the range of 200 bp to 
1000 bp (data not shown). For antibodies, it had to be ensured that they could 
recognize the respective protein following denaturation with formaldehyde. To 
establish the protocol, test-samples (K4IM, HUT78 - a T-cell tumor celline, and YT - a 
natural killer cell line [123], data not shown) in combination with an antibody that 
detects active chromatin (acetylated Histone H3 (Lys9/18)) and primers for the 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) promoter were used. The 
specific enrichment of active chromatin is measured in a PCR and validated against 
the unspecific background. The different controls performed define for DNA 
contamination of the reagents (Mock control), unspecific reactions of the StaphA cells 
(no AB control), and the specificity of the antibody (isotype control). The parameters 
were later adapted for the NCOR antibody. For precipitation, different methods were 
tested and evaluated based on binding capacity, visibility during washing steps, and 
cost. Precipitation systems tested included agarose beads, sepharose beads, 
paramagnetic beads and Staphylococcus aureus cells. Agarose, sepharose or 
paramagnetic beads were eliminated based on their poor binding capacity and 
visibility problems. Protein A-bearing Staphylococcus aureus cells were found to be 
best-working approach for the experiments. StaphA cells are commercially available, 
show high affinity to IgG, are visible during pipetting, and allow stringent washing 
steps. Visibility is very helpful for the complete removal of wash buffers without 
aspirating the samples. DNA purification using commercially available columns was 
tested, but due to the minimal amount of precipitated chromatin and its short length 
the approach was not successful. DNA was extracted using phenol-chloroform 
protocols and glycogen as inert carrier, to minimize loss of sample. Due to low 
amounts of starting material the total amount of precipitated chromatin could be 
expected to be close to detection limits. Different amounts of eluted DNA were tested 
as PCR inputs. Against prior expectations, high PCR inputs contained, despite 
extended washing and extracting steps, contaminants interfering with the enzymatic 
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reaction resulted in poor efficiency of PCR reactions. To minimize inhibitory effects 
the sample input size for the PCR was reduced to the minimum level so that it could 
be reliably pipetted. For PCR, 35 amplification cycles were necessary to sufficiently 
amplify the enriched DNA in the sample. We came to the conclusion that the ChIP 
method is only advisable to use if the proper controls are employed and the question 
asked can explicitly be answered by this method. The established protocol was 
successfully employed to investigate the binding of the transcription factor SP1 to the 
CCL5 promoter in a natural killer cell line as described in [123]. 
5.2.4.2.2 NCOR binding to the CCL5 promoter 
Based on our hypothesis, it was proposed that the NCOR could be bound to the 
CCL5 promoter, as long as the cells were not treated with an activating stimulus. 
With activation, the inhibitory complex would be replaced, allowing the formation of a 
transcriptional activation complex. This hypothesis, extended to the “indirect” effect of 
13cRA previously demonstrated, was evaluated using immortalized human dermal 
fibroblast cells (K4IM) under different stimulation conditions for NCOR modulation by 
13cRA, as described in 4.4.2. The method allowed preliminary exploration of the 
hypothesis. Based on the limited experiments that could be conducted in this regard, 
no direct binding of NCOR to the inactive CCL5 promoter could be demonstrated. 
Thus, we were unable to generate data to support the hypothesis. This hypothesis 
extended to the “indirect” effect of 13cRA previously demonstrated was evaluated 
using immortalized human dermal fibroblast cells (K4IM) under different stimulation 
conditions for NCOR modulation by 13cRA, as described in 4.4.2. The method 
allowed preliminary exploration of the hypthoesis. Based on the limited experiments 
that could be conducted in this regard, no direct binding of NCOR to the inactive 
CCL5 promoter could be demonstrated. Thus, we were unable to generate data to 
support the hypothesis. 
While the mock (see supplementary figure 4) and the isotype controls (figure 39 and 
supplementary figure 4) demonstrated no signals after a PCR with 35 cycles, 
employing the CCL5 primers, a signal was detected in the no-antibody control 
suggesting potential contamination.  
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Fig. 39: Chromatin immunopreciptiation results for CCL5, CXCL10/IP10 and NOS2. ChIP was 
performed as described in 4.4.4. Using 1x106 K4IM cells per condition, unstimulated, TNFA and 
TNFA/RA treated cells were precipitated using an NCOR antibody. After chromatin purification PCR 
was performed using primer pairs amplifying the CCL5, IP10 and NOS2 promoter. This figure displays 
a compilation of parts of the original agarose gels (supplementary figure 4) of the ChIP experiment 
discussed. Due to problems with the colour assignment after scanning the original photographs the 
colour information has been recalculated to a grey scale. CCL5 results are represented as composite, 
since the lanes of the original gel were in a different order than presented here (supplementary figure 
4). 
In addition, a strong signal was found only after an inflammatory stimulus was 
applied, and no signal was seen with 13cRA-treatment. To exclude that this 
contradictory effect was solely CCL5 dependent, we further investigated the 
promoters of two additional pro-inflammatory genes. Microarray and qPCR 
experiments demonstrated upregulation of CXCL10/IP10 and the NOS2 promoter 
after transplantation. Treatment with 13cRA decreased the expression at the mRNA 
level. Primers for both promoters were designed and evaluated in ChIP. With the 
exception of the signal in the isotype control of the NOS2 PCR, the results for the 
CXCL10/IP10 and NOS2 primers showed the same effect, as observed at the CCL5 
promoter (figure 39). Based on these contrary results it was not possible to draw a 
definitive conclusion regarding the transrepression mechanism of the 13cRA in our 
cell system. However, the preliminary results in these studies (even in the absence of 
adequate controls) could not support the original hypothesis. 
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6 Discussion 
The changes that characterize CAD include inflammation, interstitial fibrosis, tubular 
atrophy, glomerular sclerosis with basement membrane abnormalities, and chronic 
lesions. Histological examination demonstrated an accumulation of damage and 
subsequent deterioration of organ function in the transplanted rat kidneys that 
mirrored, to a significant degree, that which was seen in human disease [5, 47]. The 
goal of this study was to correlate alterations, observed in histology during the 
rejection process, with alterations in the transcriptome and select regulatory 
pathways.  
Orally applied 13cRA treatment starting just after organ transplantation had been 
previously shown to limit damage and preserve organ function [5]. By the end of the 
study (56 days after transplantation), the morphometry of the treated kidneys 
resembled that of the non-transplanted control kidneys. The second goal of this study 
was to characterize transcriptomic alterations in relevant regulatory pathways, 
induced by the treatment with 13cRA. 
6.1 Transcriptomic analysis 
Microarray analysis showed over one thousand different genes to be differentially 
regulated between the mRNA of the control kidneys and the mRNA of the 
transplanted kidneys on time points 7 days, 14 days, and 56 days after 
transplantation. To evaluate the transcriptome of the experimental kidneys, three 
major problems linked to the general method had to be considered. 
First, changes on the RNA level may not be reflected in changes on the protein level. 
To help address this protein verification was performed. 
Second, microarrays are tools for large scale investigations of gene expression, but 
the output of the analysis has to be regarded as a ratio between a control and a 
treatment group. Statistical parameters and evaluation of the output is necessary to 
define thresholds of regulation. The calculation of thresholds is also relative to the 
total number of genes present on the array, and to the number of differentially 
regulated genes. Therefore, depending on the number of genes observed to be 
regulated, the thresholds of significance will adjust. Hence, the comparison of two 
groups, with differing numbers of regulated genes is based on a different statistic, 
and therefore can be problematic. This problem could be limited by regarding the 
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microarray analysis as only a preliminary indicator of regulation, where important 
genes were later verified by qPCR before conclusions are drawn. 
Third, the microarray design only allowed evaluation of part of the transcriptome. The 
U34A microarray used here has 8000 annotated genes on the array. Hence, data is 
parital e.g. neglecting some genes and splice variants. It was necessary to 
investigate missing genes directly by qPCR to complete the picture. New generations 
of whole-genome arrays will facilitate further investigation of signal transduction. Most 
of the pathways identified to be dysregulated in this study did not demonstrate a 
significant differential regulation after the microarray analysis, due in part to 
incomplete annotation of pathway genes. 
One further challenge is the nature of the samples investigated. Samples were 
generated from whole kidney lysates. Normal kidneys consist of a variety of different 
cell types. In addition to the diverse cell types, a varying degree of infiltrating immune 
cells, in accordance to immune responses within the allograft, defines the total mRNA 
pool which is being analyzed. The origin of a specific mRNA could not be easily 
determined by this study. Some genes are uniquely transcribed by special cell types 
allowing for an estimation of relative numbers of these cells within different samples. 
By epigenetic analyses, it is also possible to differentiate the source of a specific 
mRNA. Through monitoring the epigenetic status of a control sample it becomes 
possible to evaluate whether a specific mRNA is really regulated at the transcriptional 
level, or if the number of cells producing this mRNA varies. For this kind of analysis 
genomic DNA material is required. Visualizing RNA co-localization is a method that 
makes use of frozen or paraffin embedded sections. In this approach, through in situ 
hybridization, an RNA signal can be multiplied and detected by fluorescence 
microscopy. Using different dyes for the different RNAs, it would be possible to 
identify possible co-localization of RNAs, which would give further insight into 
possible co-regulation. Unfortunately, these methods could not be used in this study, 
since they first had to be established in the rat, as to the availability of genomic 
sequences and hybridization probes. 
Employing qPCR was an important tool to investigate alterations in mRNA levels of 
genes not annotated to the microarray. qPCR allowed a verification of microarray 
results. Based in large part, on the method used for analysis of the array data 
(ChipInspector), a good correlation between microarray and qPCR data was 
observed, in general. 
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6.2 Alterations in gene expression during disease progression 
An upregulation of inflammatory effector molecules and signal transducers in 
combination with the infiltration of the organ by leukocytes were used to demonstrate 
an inflammatory milieu within the test kidneys. Inflammation that occurs in the acute 
phase of an immune response can often heal with complete functional and 
morphologic restitution. In smoldering, chronic active inflammation, not only 
“classical” inflammatory cell elements, but also activation of endothelial cells, 
epithelial cells or fibroblasts has been reported [124]. A role for inflammation in 
developing fibrosis and tissue remodeling had been well established [124].  
CAD is associated with increased TGFB1 expression [125]. In the transplanted 
kidneys of the placebo group, upregulation of profibrotic mediators, such as Tgfb1 
and Serpine1/Pai-1 was observed. The immunosuppressive effects of TGFB1 are 
contradictory to its proinflammatory role in tissues [125]. Consistent with its function 
in wound healing and repair, it is chemoattractive for leukocytes [126]. A correlation 
between intragraft TGFB1 expression and interstitial fibrosis was demonstrated in 
human renal allografts [126]. In human fibroblasts of the lung, TGFB1 was identified 
as a strong transcriptional activator of plasminogen activator inhibitor 1 (PAI-1) [127].  
The deposition of Serpine1/Pai1 is associated with ECM expansion and fibrosis [84], 
and could be observed on day 56 in animals of the placebo group. Regulation of 
Serpine1/Pai1 is dependent on the expression of inflammatory cytokines, such as 
IL1b, Il6, Tnfa and Ifng, all of which were observed to be upregulated in our model. 
BMP7, a member of the TGFB family, can suppress the expression of many 
proinflammatory cytokines and growth factors and is also a biomarker for progressive 
chronic renal disease [85, 128, 129]. BMP7 is thought to act as a counter regulator of 
TGFB1 and therefore, Bmp7 downregulation can be interpreted to enhance 
progression of CAD in this model. Tyler et al. showed in an in vitro study that the 
addition of BMP7 to TGFB-stimulated cells reduced Fsp1/S1004a expression, a 
marker of fibroblast activation [85]. The Bmps are downstream target genes of the 
WNT canonical pathway, demonstrating potential crosstalk between the TGFB and 
WNT pathways during CAD. The differentially regulated markers of fibrosis, verified 
by qPCR, are summarized in table 2. 
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Table 2. Summary of qPCR results of inflammation and fibrosis associated genes 
Gene ID Gene Symbol CAD Significant effect  
  Regulation of treatment 
Inflammation associated genes   
24770 Ccl2   K + 
25542 Ccl3   K + 
81780 Ccl5   K + 
245920 Cxcl10/Ip10   K + 
25712 Ifng   K + 
24494 Il1b   K + 
24498 Il6   K + 
24508 Irf1   K + 
314870 Irak3   K + 
24514 Jak2   K - 
25664 Pparg   K + 
25124 Stat1   K + 
24835 Tnfa   K + 
29260 Tlr4   K + 
    
Fibrosis related genes     
25365 Actg2   K + 
85272 Bmp7  L + 
29393 Col1a1   K + 
84032 Col3a1   K + 
24615 Fsp1/S100a4   K + 
59086 Tgfb1   K + 
24617 Pai-1   K + 
81818 Vim   K + 
Table 2: Arrows indicate up or downregulation of gene expression in relation to the normal control 
kidneys. Further, statistically significant effects of the treatment, on the expression of genes are 
denoted. 
Fibrosis in basal membranes and interstitial tissues results from an excessive 
synthesis of interstitial collagens, such as type I and III [81, 84]. Epithelial to 
mesenchymal transition (EMT) has been proposed to underlie renal fibrosis [130]. 
EMT is linked to the assembly of nuclear beta-catenin and activation of transcription 
factors such as SNAIL (Snai1 in the rat), which are necessary to downregulate the 
expression of E-cadherin and thereby moderate cell motility. While stabilization of 
protein expression and nuclear enrichment of beta-catenin could be determined in 
our study by immunohistochemistry, no changes were observed in the expression of 
beta-catenin at the mRNA level. Importantly, we did not detect the upregulation of 
Snai1 or the downregulation of E-cadherin expression, thought to be mandatory for 
EMT. In this regard, evidence of “complete” EMT could not be detected.  
Progressive upregulation of Fsp1/S100a4 was found in the model. The expression of 
this gene has been implicated as a marker for the generation of fibroblasts through  
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EMT [80, 131]. However, the notion that FSP1/S100A4 is specific for fibroblasts has 
been put to question by the observation that FSP1/S100A4 is also expressed by 
lymphocytes, macrophages and granulocytes [132-135]. Indeed, Le Hir et al. 
demonstrated that a large fraction of FSP1/S100A4 positive cells in models of 
peritubular inflammation were leukocytes [132]. Thus, the increase in Fsp1/S100a4 
mRNA could be explained, to a significant degree, by the mononuclear infiltrate 
present in our model. The same may apply for the “mesenchymal” marker vimentin, 
whose upregulation is accepted as an indication of the change of an epithelial 
phenotype towards a mesenchymal or fibroblastoid phenotype. Despite the broadly 
discussed EMT context, Gröne et al. discuss this filament protein as a marker for 
mitosis, observed during nephrogenic repair [136]. This is supported by the results of 
Nakatsuji et al. [137], stating vimentin to be an upregulated marker of regenerating 
epithelial cells, further suggesting an important role for vimentin-positive tubule cells 
in promoting proliferation of myofibroblasts, without putting vimentin in any EMT 
context. The notion of Katoh [138], that vimentin is a target of WNT non-canonical 
signaling in stem cells, puts vimentin and its possible role in CAD into a whole new 
context.  
Despite the fact that EMT could not be demonstrated to occur in our renal allograft 
model, evidence could be found for the dysregulation of a series of EMT-associated 
signal transduction pathways. It is thought that the TGFB, NOTCH, hedgehog, and 
WNT pathway contribute to EMT (and fibrosis). 
The NOTCH pathway plays a crucial role in kidney development, while in the mature 
kidney, only very little active NOTCH1 receptor can be detected [28]. The NOTCH 
pathway has been discussed in the context of EMT [17], and has been proposed to 
play a role in the pathogenesis of glomerular kidney disease [28]. No differential 
regulation of the NOTCH pathway genes was observed by qPCR analysis, 
suggesting that transcriptional activation of this pathway could not be demonstrated 
in the context of our study.  
Hedgehog (HH) signaling remains active in the adult where it helps maintain tissue 
homeostasis [91]. HH has been recognized in different types of cancer [92], stem cell 
biology, and tissue repair during chronic persistent inflammation [31]. Moreover, Le et 
al. could demonstrate, in an in vivo mouse model of wound healing, that 
cyclopamine-induced HH signaling-disruption impaired normal wound healing [32]. 
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Microarray and subsequent qPCR analyses revealed alterations in the expression of 
hedgehog pathway genes. 
The mRNA of desert hedgehog (Dhh), one of the three vertebrate HH ligands, the 
receptor and target Ptch1, the target gene Sfrp1, and several WNT ligands was found 
to be upregulated during CAD. This suggested pathway activation. Target genes of 
the HH pathway exert stimulatory signals, including WNT ligand expression, as well 
as upregulation of WNT inhibitors (Sfrp1). In contrast, the HH pathway ligands indian 
hedgehog (Ihh), sonic hedgehog (Shh), the receptor Lrp2, and target genes Bmp4 
and Bmp7 were downregulated with CAD. The receptor LRP2, also called megalin, is 
an endocytotic scavenger receptor expressed in the adult kidney in the brush border 
of the renal proximal tubule [36]. Receptor-mediated endocytosis facilitates the 
clearing of substances – such as nutrients, lipoproteins, hormones, vitamins, and 
enzymes by tubulus cells – and also moderates signaling through direct activation of 
signaling cascades [36]. Decreased renal LRP2 expression has been demonstrated 
in diseases characterized by proteinuria and defective tubular re-uptake of filtered 
proteins [36]. In an in vitro system of proximal-tubule-derived cells, TGFB1-induced 
reduction of LRP2 expression could be observed in a time and dose-dependent 
manner [37]. Caruso-Neves et al. further identified LRP2 as a sensor of albumin that 
determines whether tubule cells are protected or injured by albumin which would 
result in apoptosis [38]. Alterations in Lrp2 expression, as observed in our model, fit 
into a model that integrates non-specific protein uptake, HH signaling and fibrosis-
mediated apoptosis of renal tubule structures, all induced by the genera insult to the 
organ. 
HH and TGFB signaling are further connected by the expression of BMPs which are 
antifibrotic HH target genes. HH pathway genes such as Lrp2, that are known to be 
influenced by TGFB1, as well as TGFB1 antagonists, such as BMP7, were 
downregulated during progression of CAD. 
While a central role for the biology of TGFB1 in human and experimental models of 
renal fibrosis has been well documented [139, 140], the potential role of the WNT 
pathway is less clear. There are several points at which potential crosstalk or cross-
regulation between the canonical WNT and TGFB1 signaling pathways may occur. 
A role for the WNT canonical pathway in renal interstitial fibrosis has been evaluated 
in an in vivo mouse model [141]. In our model of progressive CAD, a dynamic 
modulation of specific elements of the WNT signaling pathway was observed.  
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The Wnt gene expression profile suggested activation of the canonical and WNT-
Ca2+ pathways, but did not support activation of the PCP pathway during CAD [41].  
Seven Wnt genes were found to be differentially regulated at the mRNA level in our 
rat model (Table 1). The subcategorization of WNT action can be difficult as 
individual WNTs may influence several WNT pathways. For example, WNT6 has 
been assigned to the canonical WNT pathway by Kirikoshi et al. [142], whereas 
Nishizuka et al. [143] report WNT6 to be a part of the WNT-Ca2+ pathway. During 
development, restricted zones of intense canonical WNT signaling drive 
nephrogenesis in fetal kidney [144]. WNT7b has been shown to be a key regulator of 
the ductal architecture that establishes a functional physiologically active mammalian 
kidney [145]. Here a progressive loss of expression of Wnt7b was associated with 
CAD. The modulation of select WNT genes during progressive CAD suggests a fine 
control of distinct pathway branches associated with these pathophysiologic events. 
While macrophages play a prominent role in the development of renal fibrosis and 
Wnt2, Wnt5a and Wnt7b expression have been linked to macrophage infiltration in 
various contexts [146, 147], these WNT genes were not increased in expression 
during CAD. Since expression of 17 WNT ligands was seen in the control kidneys, 
resident kidney cells appear to represent the principal source of WNT ligands during 
CAD. The ability to further dissect WNT-ligand specific pathway regulation will help to 
devise potential programs to modulate this pathway. 
In the adult, WNT signaling plays an important role in the control of tissue self-
renewal [148]. Canonical WNT signaling promotes cell proliferation, tissue expansion 
and the control of cell fate determination and terminal differentiation [110]. 
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Table 3. Summary of qPCR results of hedgehog and WNT pathway genes 
Gene ID Gene Symbol CAD Significant effect  
  Regulation of treatment 
Hedgehog pathway     
29499 Shh  L + 
16147 Ihh  L + 
620711 Dhh   K + 
29216 Lrp2  L + 
89830 Ptch1   K + 
140589 Gli1   K - 
84402 Sfrp1   K + 
25296 Bmp4  L - 
85272 Bmp7  L + 
    
Canonical WNT pathway   
24882 Wnt3   K - 
293990 Wnt8b  L + 
316527 Wnt10a  L + 
161452 Lef1   K + 
24817 Tcf1  L + 
25296 Bmp4  L - 
25406 Cd44   K + 
25661 Fn1   K + 
24577 Myc   K + 
25335 Mmp7   K + 
24599 Nos2   K + 
    
WNT-Ca2+ pathway     
316526 Wnt6   K + 
114850 Wnt7a   K + 
315196 Wnt7b  L + 
25023 Prkcb1    K + 
81749 Prkch    K + 
307231 Nfatc1_pred   K + 
311658 Nfatc2   K + 
Table 3: Arrows indicate up or downregulation of gene expression in relation to the normal control 
kidneys. Further, statistically significant effects of the treatment, on the expression of genes are 
denoted. 
Transient upregulation of WNT canonical pathway has been described in the context 
of wound healing [112, 113]. Abnormal WNT signaling has been associated with 
many diseases including pulmonary fibrosis [40]. In the experiments detailed here the 
activation of each sub-pathway appeared to be guided through the selective 
modulation of specific transcription factors associated with the individual pathway and 
downstream target genes. The transcription factors LEF1 and Tcf1 are associated 
with activation of the canonical pathway. Lef1 target genes, including Nos2, Fn1, 
Mmp7 and Cd44 [114], showed pronounced upregulation in the model. In contrast, 
Tcf1 was progressively downregulated. 
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Upregulation of the canonical WNT target gene Fn1 links the observed fibrosis 
directly to activation of this pathway. The expression of Nos2, a canonical WNT 
target associated with inflammation and macrophage activation [149] was increased 
with CAD. Mmp7 showed the strongest regulation of any WNT target gene studied 
(over 1000-fold). Mmp7 is linked with ECM remodeling and the posttranslational 
modification of growth factors. These actions are thought to facilitate tissue milieu-
dependent “sensing” of pathways (e.g. TNF and TNFRI & II) [150]. The canonical 
WNT target gene Cd44 plays a role in leukocyte infiltration and has been linked to 
chronic inflammatory disease [151]. CD44 is a receptor for hyaluronan and 
moderates cell-cell/cell-matrix interactions [152]. CD44 has also been shown to 
promote the activation of TGFB1 in fibroblasts via an MMP-dependent mechanism 
[153]. 
Activation of the canonical WNT pathway resulting in the upregulation of Cd44 and 
Mmp7, and the effects seen on TGFB1 biology highlight the potential interplay 
between the WNT and TGFB pathways during CAD and suggests a direct role for 
these pathways in the generation of a profibrotic tissue milieu. Rouschop et al. have 
suggested that de novo expression of CD44 in an injured kidney contributes to the 
development of fibrosis, at least in part, through enhanced TGFB signaling [152]. 
Our analysis also suggests a parallel activation of the WNT-Ca2+ pathway during the 
development of CAD. The WNT-Ca2+ pathway is unique to vertebrates and plays 
critical roles in orchestrating the cellular events that characterize vertebrate 
development and morphogenesis. In contrast to the canonical WNT pathway, target 
genes for the WNT-Ca2+ pathway are not well defined, but are generally thought to 
be targets of the NFAT family of transcription factors. Increased expression of the 
WNT-Ca2+ pathway genes Prkcb1 and Prkch and the transcription factors 
Nfact1_pred and Nfact2 were associated with CAD. In this setting, the transcriptional 
regulators of the NFAT family function as molecular integrators of calcium signals 
with other signaling pathways, including MAPK, WNT or NOTCH [154]. Bourajjaj et 
al. [155] recently demonstrated the importance of the WNT-Ca2+ pathway in myocyte 
hypertrophy and pathological cardiac remodeling during heart failure. Similar 
regulatory events may help dictate the pathophysiology seen in renal fibrosis and 
CAD. While WNT signaling is essential for renal development, select components of 
the WNT signaling pathway were found here to be modulated during progression of 
CAD. The dysregulation of these components during CAD suggests that these 
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pathways may be potential targets for therapeutic intervention in CAD and other 
progressive renal diseases. 
6.3 Therapeutic intervention of disease progression by 13cRA 
The therapeutic effect of 13cRA on transcriptomic profiles and regulatory pathways 
was further evaluated with the treated kidneys appeared essentially “normal” 
following treatment by morphometry. The transcriptomic analysis did reveal 
significantly altered expression of genes. Hierarchical clustering revealed that with 
time, the overall gene expression profiles of the 56 day-treatment group regained a 
similar expression pattern, as compared to the normal kidney controls. The treatment 
could not prevent alterations in gene-expression altogether, as observed by 
numerous alterations at early time points in the treatment group. The changes were 
rather reversed by the prolonged treatment, as observed on day 56 after 
transplantation. The kidneys of the placebo group, as well as kidneys from the 
treatment group, differ from the control kidney in the amount of immune cells. 
Treatment could not eliminate infiltration completely, but may have induced tolerance. 
This assumption is based on the similarity of expression patterns 56 days after 
treatment, despite a detectable infiltrate. 
Analysis of gene expression of kidney tissue does not allow us to draw conclusions 
about potential events occurring systemically. A reduction in proinflammatory stimuli 
could result form a systemic effect on leukocyte priming or homing. Previous studies 
have shown a reduction in mononuclear infiltration with treatment in the same model 
[5]. In addition, effects of 13cRA on the infiltrate present in the kidney are also 
possible. The overall effect may thus result from a combination of effects [5]. Since 
inflammation is thought to help trigger the development of fibrosis, changes in the 
nature or quantity of the infiltrate will influence the outcome of the disease. A 
significantly-attenuated upregulation could be observed in all inflammation and 
inflammatory signal transduction-associated genes, with the exception of Jak2 
(5.2.3). These effects on gene expression reflect our observations in morphometry 
[5]. Since many of the genes discussed in the context of inflammation are mainly 
transcribed by immune cells, it has to be noted that a reduction of mRNA measured 
in the 13cRA treated animals is probably partially due to the decrease of leukocyte 
infiltrates in these organs. Therefore, the overall effects result from the combination 
of regulation of gene expression and decreased infiltrate of immune cells. 
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To gain further insight into the potential mechanism of 13cRA on the promoter level, 
experiments investigating an indirect repression mechanism were performed. Adams 
et al. [5] excluded a transrepression mechanism involving direct binding of the 
RAR/RXR receptors to the response elements of the promoter of the exemplary gene 
CCL5. Pascual et al. [59] showed that posttranslational modification of a nuclear 
receptor (PPARG) led to the adherence of a nuclear corepressor (NCOR) at the 
promoter, preventing transcriptional activation of an inflammatory gene. We 
hypothesized that a NCOR-dependent mechanism might be similarly involved in the 
indirect transrepression mechanism described for CCL5 transcription (i.e. that NCOR 
would normally be found bound to the promoter and blocking expression). Stimulation 
would result in loss of NCOR, thus allowing transcription from the promoter. 
The experiments were difficult to perform in part due to problems with generating 
sufficient cell numbers. Thus only preliminary data could be presented. Problems with 
the method included compromising signals in the isotype control allowed no definitive 
conclusion to be drawn of the ChIP experiment. The signal in the no-antibody control 
suggests an unspecific binding of the preblocked StaphA cells to the chromatin. A 
potential explanation for the signal seen in these controls, and not in the PCR 
samples using NOS2 primers, is a combination of insufficient washing with a higher 
abundance of CCL5 and CXCL10/IP10 chromatin as compared to NOS2. Taking the 
differences of the input controls into consideration normalization against total input 
would have reduced the no antibody control signal compared to the NCOR sample 
signal. Evaluation of this experiment by quantitative PCR was not performed, but 
could help to interpret future experiments. For a definitive answer to these questions 
a new cell system should be employed that allows for larger amounts of starting 
material. Problems such as the ratio of background to enriched chromatin, non-
uniform loss of sample during washing and purification and high numbers of PCR 
cycles are often found when only small sample sizes can be used and should 
therefore be avoided. 
In parallel experiments out side the focus of this thesis, where large numbers of cells 
could be used, the general method was efficiently applied to assess the binding of 
the transcription factor SP1 to the CCL5 promoter in a natural killer cell line [123]. 
Retinoic acid has been reported to modulate the generation of helper T cell 
populations from an inflammatory towards an anti-inflammatory, self tolerant 
phenotype through various mechanisms. For example, by promoting FOXP3-positive 
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regulatory T cells (Tregs) [119, 156]. In vitro, TGFB-induced FOXP3 expression in T 
cells was found to be unstable [119], but the protein could be stabilized by retinoic 
acid treatment [157]. Despite the upregulation of FOXP3 in vitro, treatment of 
experimental autoimmune encephalomyelitis (EAE) with retinoids was found to 
suppress Th17 cell function without promoting Foxp3 expression [158]. In an in vivo 
mouse model, mice infected with Listeria monocytogenes, a reduction in Th17 cells 
was observed following retinoic acid administration which acted through a reduction 
in the transcription factor “RAR-related” orphan receptor gamma t (RORgt). This 
factor is important for Th17 development [157]. We also looked at the expression of 
genes specific for Tregs and Th17 cells to investigate whether 13cRA might induce 
tolerance through influencing the T cell milieu. Upregulation of Foxp3 was observed 
in all groups. Differences in Foxp3 expression were statistically significant between 
the placebo and the treatment group on day 56, with reduced expression observed in 
the treatment group. Genes involved in the development of the Th17cell lineage 
including Il6, Il6r, Il21, and Tgfb1 were upregulated, but none of the groups 
demonstrated a regulation in Il17 expression. This suggested that while a Th17-
promoting regulatory milieu was present in the kidney, no upregulation at the gene 
expression level of Il17 was observed. This may be due to a strong allo-Th1 
response that suppresses the Th17 lineage, as represented by upregulated Ifng. 
With regards to the Tregs, even though a stimulatory effect of retinoic acid on the 
Foxp3 expression has been described, our data could not demonstrate this effect at 
the mRNA level. On the other hand, there is a clear downregulation of inflammation 
in the kidneys of 13cRA-treated rats, as shown by a decrease of inflammatory as well 
as suppressive cytokines on day 56, reflecting a decrease in kidney inflammation 
and, concomitantly, the need for counter-regulation. Further studies investigating  
T cell lineages by using in vitro systems will have to be employed to better 
characterize the effect of 13cRA on the immune milieu. In summary, we found a 
reduction in inflammation and fibrosis by morphology and downregulation on the 
gene expression level (see 5.2.3). In addition to alterations of the kidney tissue itself, 
effects might be due to a shift in amount and effector type of infiltrating cells of the 
immune system. 
The roles of the HH and the various WNT pathways during the progression of CAD 
were discussed in 6.2. Having established that a well defined regulation of these 
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pathways was observed during CAD, we investigated the potential influence of 
13cRA treatment on the activation status of these pathways. 
Retinoic acid (RA) has complex and pleiotropic functions during vertebrate 
development [116]. RA is recognized as an important signaling molecule which can 
influence developmental pathways including HH [116]. In vitro, SHH and RA have 
been shown to exert synergistic effects on the differentiation of mesenchymal stem 
cells [117]. 
13cRA treatment appeared to reverse the CAD associated effects on the HH 
pathway. Steady state levels of mRNA for HH pathway genes were reversly 
regulated. Genes, observed to be upregulated during CAD, were downregulated in 
the treatment group and genes initially found to be downregulated during CAD, were 
observed to be upregulated by treatment. 13cRA treatment appeared to alter gene 
expression of HH pathway genes more in line with the control normal kidney and thus 
potentially, to re-establish normal tissue homeostasis. For example, the extreme 
downregulation of the receptor Lrp2 observed during CAD was prevented by 13cRA 
treatment. In an in vitro system, upregulation of megalin (Lpr2) mRNA and protein 
expression after retinoic acid treatment could be demonstrated [159, 160]. The 
decreasing Lrp2 mRNA levels, measured in our study, could also reflect apoptosis of 
the main Lrp2 expressing cells. Hence, the minor changes in expression observed 
after treatment could indicate better survival of the cells that express Lrp2. A direct 
stimulation of Lrp2 transcription by retinoic acid, as described in the literature [160], 
could also explain the effect observed. 
To address this question, we investigated the effect of 13cRA on different cell 
systems in vitro (data not shown). Unfortunately, all of the cell types tested including 
a human proximal tubule cell line, a mouse tubule cell line, and primary rat tubule 
cells did not show stable expression of the Lrp2 gene. Thus, neither stable Lrp2 
expression, nor a reproducible stimulation of Lrp2 expression could be demonstrated 
in vitro. With a better cell culture system, it may be possible to better address this 
question. Of all HH pathway genes investigated, Lrp2 and the ligand Ihh 
demonstrated almost equal regulation. Although in the literature only SHH is 
discussed to be an LRP2 ligand, this closely linked expression suggests potential 
interplay between SHH and LRP2. 
The HH target genes Bmp4 and Bmp7, initially downregulated in CAD, returned to 
normal levels after 13cRA treatment. A direct stimulatory effect of retinoic acid on 
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Bmp7 expression had been previously demonstrated in vitro [161]. Upregulation of 
the anti-fibrotic Bmp7 expression may represent an important means by which RA 
exerts its anti-fibrotic effects. Katoh et al. reported that mesenchymal BMP can 
induce the indian hedgehog gene (IHH) in gastrointestinal epithelial cells which led to 
the induction of WNT2B and BMP4 through activation of epithelial hedgehog [162]. A 
similar effect in regulation of Ihh, Bmp4 and Wnt2b gene expression was observed in 
the 13cRA treated rat kidneys, further suggesting a close connection between HH 
and WNT signaling pathways. 
Four of the 17 WNT ligands expressed in the kidney tissue were downregulated 
during CAD. 13cRA treatment resulted in the upregulation of Wnt2b and Wnt10a, and 
at the same time, in an increased downregulation of Wnt7b and Wnt8b. In the same 
manner that specific activation of WNT signaling could be observed during CAD 
progression, a specific regulation could be seen in response to 13cRA treatment. 
More information concerning the effect of the individual WNT ligands on downstream 
target gene activation will help clarify the consequences of dysregulation. 
A link between retinoids or members of the steroid family with the canonical WNT 
pathway is well defined [111]. Nuclear receptors including PPARG and the RAR 
receptor bind beta-catenin and/or regulate activation of WNT target genes [118]. RAR 
can form a complex with beta-catenin competing with TCF/LEF1 for the binding to 
DNA and thus suppressing activity [111] (the inhibitory relationship between the HH 
and WNT pathway has already been addressed in 5.1.3.1). In response to RA, beta-
catenin protein levels of tumor cell lines increased significantly at the membrane, 
although mRNA levels remained constant [163]. 
Similar effects were observed for the WNT canonical and Ca2+ pathways. 
Upregulation of the transcription factor Lef1 and the WNT canonical target genes 
Cd44, Fn1, Nos2, Mmp7, and Myc seen with CAD were diminished in comparison to 
the placebo group. In contrast, the observed downregulation of the transcription 
factor Tcf1, as well as the target gene Bmp4 was attenuated by treatment. Treatment 
appeared to specifically reduce the activation of the fibrosis-promoting part of the 
WNT canonical pathway as evidenced by the effects seen on fibronectin, Cd44 and 
Mmp7. 
Increased expression of the WNT-Ca2+ pathway genes Prkcb1 and Prkch and the 
transcription factors Nfact1_pred and Nfact2 was observed to be attenuated through 
treatment. As already discussed in 6.2, vimentin is a target of the non-canonical WNT 
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pathway, moreover, CD44 was discussed as also acting as a non-canonical WNT 
target in stem cells [138]. This links not only the intermediate filament protein 
vimentin to fibrosis and the WNT-Ca2+ pathway, but also demonstrates the strong 
context-dependency of the determination of the WNT signaling cascades in general. 
 
Fig. 40: The roles of HH and WNT canonical pathway in transplantation-induced fibrosis. 
Figure 40 summarizes up or downregulation of HH and WNT canonical pathway genes, as observed 
by qPCR analysis. Green indicates downregulation of gene expression, while red indicates 
upregulation. Symbols denote a positive, as well as a negative regulatory relationship between both 
pathways. The left diagram displays a model of inflammation-induced dysregulation of pathway 
activation, resulting in fibrosis, as observed in the rat model. The right diagram displays possible 
influence of RA treatment and a shift observed in pathway regulation.  
From studies of embryonic development, RA has been shown to act as a major 
integrator of signaling pathways that control apoptosis, proliferation and 
differentiation [116]. Similar actions may help explain the positive effects seen in our 
CAD model. Aside from transcriptional regulation, 13cRA might influence the stability 
of RNA or Protein, RNA turnover or the regulation of microRNAs (miRNA). Direct 
effects of RA treatment on pathway activation could not be easily investigated in our 
system, but overall transcriptomic effects suggest a predominant induction of 
hedgehog pathway genes, and a reduction in the activation of the WNT pathway. The 
indian hedgehog gene Ihh is also discussed as an antagonist of WNT signaling in 
colonic epithelial cell differentiation [104]. The hedgehog pathway target gene 
secreted frizzled protein 1 (Sfrp1) which is a WNT inhibitor [100]. Both genes were 
upregulated after treatment. A tight and complex relationship between signal 
transduction and treatment is suggested. 
In conclusion, we propose a model that integrates effects generated by the 
transplantation-process. Inflammation factors induce an imbalance in the wound-
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healing and homeostatic processes, marked by dysregulation of hedgehog and Wnt 
pathway activation (see figure 40). The combined effects of chronic inflammation and 
dysregulation of these central regulator pathways lead to fibrosis and organ 
deterioration. Treatment with 13cRA, not only attenuated disease progression, but 
even reversed early effects of CAD. The overall effects of the treatment consist of 
potentially direct effects on fibrosis and inflammation associated gene expression, as 
well as a specific modulation, observed in hedgehog and WNT pathways activation. 
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7 Abbreviations 
13cRA 13-cis retinoic acid 
CAD Chronic allograft dysfunction 
CCL CC- Chemokine ligand 
CD Cluster of differentiation 
CEL Cell intensity file 
ChIP Chromatin immunoprecipitation 
CTNNB1 Beta-catenin 
CT Cycle Threshold 
DAVID Database for Annotation, 
 Visualization, and Integrated Discovery 
ECM Extra cellular matrix 
EMT Epithelial to mesenchymal transition 
FC Fold change 
GO Gene ontology 
HH Hedgehog 
IFN Interferon 
IHC Immunohistochemistry 
IL Interleukin 
K4IM Immortalized synoviocyte line K4WT 
KEGG Kyoto Encyclopedia of Genes and 
 Genomes 
LEF1 Lymphoid enhancer binding factor 1 
NCOR Nuclear Corepressor 
NFAT Nuclear factor of activated T-cells 
PPAR Peroxisome proliferator-activated 
 receptor 
StaphA Staphylococcus aureus  
TGFB Tumor growth factor beta 
WNT Combination of “wingless” and “INT” 
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Symbols: 
Molecular interaction or relation of gene 
 products 
 Indirect effect of regulation 
 Inhibition of expression 
 Molecule, mostly chemical compound 
 Dissociation of proteins 
Gene product or protein 
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9 Supplementary data 
Supplementary table 1: Oligonucleotides utilized for qPCR. Part 1 
Assays on demand    
Gene  Assay ID  
Eukaryotic 18S rRNA 4310893E  
    
Assays on demand   
Gene ID Gene Symbol Assay ID  
85272 Bmp7 Rn01528886_m1  
84353 Ctnnb1 Rn00670330_m1  
24508 Irf1 Rn00561424_m1  
161452 Lef1 Rn00679641_m1  
29216 Lrp2 Rn00667205_m1  
25335 Mmp7 Rn00563467_m1  
24599 Nos2 Rn00561646_m1  
4851 Notch1 Rn01758625_m1  
25124 Stat1 Rn00583505_m1  
84382 Tcf4 Rn00584481_m1  
    
Assays designed   
Gene ID Gene Symbol Sense (5'->3') Antisense (5'->3') 
25712 Ifng AACAGTAAAGCAAAAAAGGATGCATT TTCATTGACAGCTTTGTGCTGG 
  Probe  
  CGCCAAGTTCGAGGTGAACAACCC  
    
QuantiTec Primer Assays  
Gene ID Gene Symbol Assay ID  
83502 Cdh1 QT00176288  
140589 Gli1 QT001586662  
29146 Jag1 QT00193424  
24514 Jak2 QT00189182  
81818 Vim QT00178724  
    
Oligonucleotides for qPCR, self designed  
Gene ID Gene Symbol Sense (5'->3') Antisense (5'->3') 
25365 Actg2 GGGATCCTGACCCTCAAATAC AGGAGTGGTGCCAGATCTTCT 
29134 Axin2 AAAACGGATTCAGATCCTTCAA GTGGCTGGTGCAAAGACATA 
25296 Bmp4 TCTGTCAAGACACCATGATTCC TCCTAGCAGGACTTGGCATAA 
24245 Camk2b GTCAGCTAGAGATCACCAGAAGC ATGGAGGCGTACAATGTTGG 
24246 Camk2d GGATCAAGGGCTCCACAG CGTCCTTCAGGCACCAAG 
24770 Ccl2 AGATGCAGTTAATGCCCCAC CGACTCATTGGGATCATCTTG 
25542 Ccl3 CTATGGACGGCAAATTCCAC AGGCATTCAGTTCCAGCTC 
81780 Ccl5 TGCTGCTTTGCCTACCTCTC CTTGAACCCACTTCTTCTCTGG 
58919 Ccnd1 ATGCTAGAGGTCTGCGAGGA CAGAGACAAGAAACGGTCCAG 
25406 Cd44 CAGCAGCAGATCGATTTGAATA CTGTAGCGGCCATTTTTCTC 
29393 Col IaI CTGGTACATCAGCCCAAACC CGAACTGGAATCCATCGGTC 
84032 Col IIIaI GAATGGTGGCTTTCAGTTCAG GCTGGAAAGAAGTCTGAGGAAG 
113927 Csnk1a1 ACCCAGCCTCGAAGACCT ACTGATCATCTGGTCAGCTAACAT 
3627 Cxcl10/Ip10 GCGGTGAGCCAAAGAAG CAGGAGAAACAGGGACAGTTAGG 
620711 Dhh CCAACTACAACCCCGACATAA TGCAACGCTCTGTCATCAG 
171548 Dkk3 AGGTTCACAAGATAACCAACAACC TTGCCTTCTCCATCCTCTACA 
303811 Dvl3_pred CTTCAATGGAACGCACAGG TAGCATGAGGGTGGAAGGAC 
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Supplementary table 1: Oligonucleotides utilized for qPCR. Part 2 
Oligonucleotides for qPCR, self designed  
Gene ID Gene Symbol Sense (5'->3') Antisense (5'->3') 
25661 Fn1 GCAAGCCAGTTTCCATCAAT GACATCCGTCACCTGCATC 
24615 Fsp1 GCCTAGCTTCCTGGGGAGA CTTCATTGTCCCTGTTGCTGT 
84027 Gsk3b TTCAACTTTACCACTCAAGAACTGTC AGCATTAGTATCTGAGGCTGCTG 
84399 Ihh CCCAACTACAATCCCGACAT AGTTCAGACGGTCCTTGCAG 
25325 Il10 CTTTCAAAAGAAGGACCAGCTG GCAACCCAAGTAACCCTTAAAGT 
24494 IL1b TCGACAGTGAGGAGAATGACC GGCTTGGAAGCAATCCTTAAT 
24498 Il6 TGAGAAAAGAGTTGTGCAATGG TTTTCTGACAGTGCATCATCG 
314870 Irak3_pred CCACCTAACTCGAAGCCTGT CAGGAACAAGAACATTATCCACTG 
50658 Mapk9 CCAAGGAATTGTTTGTGCTG TCACGGTAGGCTCTCTTTGC 
24577 Myc GTGGAAAACCCGACAGTCAC TGTTAGCGAAGCTCACGTTG 
307231 Nfat1_pred CCTCGTATCAGTGGGCAAAG ATGAAGGCCTCATGTATGACGTT 
307820 Nfat5 CCTTGAAAGCAATGAAAACGA TGATCAGGGCATTAGGAAGG 
361400 Nfatc 3 ACTCCTATATTTCGCACATCTTCA CACATTGTCCAAAGTGAGTTGG 
305897 Nfatc 4 ATTGAGAGGGGCCTGAT CCGCTTGTTGCTGTACTCAG 
311658 Nfatc 2 GCAGCTCCACGGCTACAT ACTTGGTAGAAGGCGTGTGG 
24617 Serpine1/Pai-1 TCCTCCACAGCCATTCTAGTC CGAACCACAAAGAGAAAGGATC 
24654 Plcb1 GCAGGTCCAAGTGTTGATTG ACTGACATCTGCCCTTTCTTG 
25664 Pparg TGTGGGGATGTCTCACAATG GATCTCCGCCAACAGCTTC 
24674 Ppp3ca GGCACCTAACAGAGTATTTCACG CCATACAGGCGTCATAAACG 
25023 Prkcb1 GCAAAGGGCTAATGACCAAA AATGTCTCGTTCAAATTCAG 
81749 Prkch TCTGGGGAGTATTTGGGAAAC  GGCAAGTGCAGGCTGTAAC 
89830 Ptch1 GATTTCCAAGGGGAAGGCTA AACTTGCCGCAGTTCTTTTG 
24705 Rara GGGGAACTCATCGAGAAGG GCTGTTGTTCGTAGTGTACTTGC 
81762 Rock1 TGGAAGACTTACGGAAAGCAAG ATTCGCTTCTTCTAACTGCTTCTG 
25271 Rxra ATCTTTGACAGGGTGCTAACG AGCTCCGTCTTGTCCATCTG 
361801 Rxrb TTTTCCTCCCTACCTCTGGAC GGAGAAGGACGCAATGAGG 
83574 Rxrg GGGTCTCTGGTGAAACACATC CAGCTATACACCCCGTAGTGC 
84402 Sfrp1 GAAGCCCCAAGGTACAACAG GATGGCCTCCGATTTCAAC 
310552 Sfrp2 TGCAAAACTAAGAACGAGGATG GATTTTCAGTGCGAAGTCATTTT 
89803 Sfrp4 TCGGTGCAAGTGCAAAAAG TTTTGGCATGAATAACATAGCTG 
309377 Sfrp5_pred GTGCTCCAGCGACTTCGT TCCCCATTGTCTATCTTGATCTC 
29499 Shh CAGGCTTCGACTGGGTCTAC ACGGAGTTCTCTGCTTTCACA 
29357 Smad2 CTCTCCGGCTGAACTGTCTC GTAACTGGCTGCAAATCCAAG 
25631 Smad3 CCAGTGCTACCTCCAGTGTTG GGAATGGCTGTAGTCATCCAG 
50554 Smad4 TCACTATGAGCGGGTTGTCTC CTTGGTGGAGCATTACTCTGC 
116490 Snai1 CGTGTGTGGAGTTCACCTTC CCAGGAGAGAGTCCCAGATG 
24817 Tcf1 GATCACAGACACCAACCTCAG GTGTCTGAGGTGAAGACCTGC 
24253 Tcf5 ACGACTTCCTTTCCGACCTC GGCTCACGTAACCGTAGTCG 
59086 Tgfb1 CCAAGGAGACGGAATACAGG GTTTGGGACTGATCCCATTG 
81809 Tgfb2 GACATGCCGTCCCACTTC CACTGAGCCAGAGGATGTTGTA 
3851 Tgfb3 CCATAAATTCGACATGATCCAG GACACATTGAAACGGAAAACC 
24835 Tnfa CCCAGACCCTCACACTCAG TTTGCTACGACGTGGGCTA 
29260 Tlr4 GATTTATCCAGGTGTGAAATTGAGA TGTCAGTACCAAGGTTGAGAGC 
114557 Wif1 ATTCCCGTCAATATCCACTCC GCCATGATGCCTTTATCCA 
24881 Wnt1 GATGGTGGGGCATCGTG GGGCTCTAGCACCAGCTGTA 
114487 Wnt2 GGTGGTACATGAGAGCGACAG GACCTGGCACATTGTCACAC 
116466 Wnt2b CGTCCTGGTGGTACATAGGG AGACCCGGGATGTTGTCAC 
24882 Wnt3 CCCGCTCAGCTATGAACAAG TCAGGTGCATGTGATCCAG 
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Supplementary table 1: Oligonucleotides utilized for qPCR. Part 3 
Oligonucleotides for qPCR, self designed  
Gene ID Gene Symbol Sense (5'->3') Antisense (5'->3') 
303181 Wnt3a CTCTGCCATGAACCGTCAC CGGATAGTCCGTGGCATTT 
84426 Wnt4 CTGTGACCGGACAGTACACG ATGTTGTCCGAGCATCCTG 
64566 Wnt5a TTCTTGGTGGTCCCTAGGTATG GAGAAAGTCCCGCCAGTTG 
282582 Wnt5b GCACTGGGATGGGTTGAG AGCGACCACCAGGAGTTG 
316526 Wnt6 TTTCCGACGCTGGAACTG AGCTGTCTCTCGAATGTCCTG 
114850 Wnt7a CCCGAACCCTCATGAACTTAC CATGGCACTTACACTCCAGTTTC 
315196 Wnt7b TCATGAACCTTCACAACAATGAG GTACATGAGCCCGACACTCC 
291678 Wnt8a CCCAAGGCCTATGTGACCTAC TTACACTCTTCCATGCCCATC 
293990 Wnt8b GGAGTGCTAACCGGGAGAC CAGGGTGTACATAACTCCAGCAG 
287357 Wnt9a CCCTGGAGTGCCAGTACC TCCTTGAAGCCTCGCTTG 
303586 Wnt9b GGCATCAAGGCTGTGAAGAG CAGCACAGGAGCCTGACAC 
316527 Wnt10a CACGCATGAGACTCCACAAC CTTTCGCCGCATGTTCTC 
315294 Wnt10b GCGGGTCTCCTGTTCTTG GGCTCACCGGGAAGTTTTAG 
140584 Wnt11 TGACATGCGCTGGAACTG GGCATACACGAAGGCTGAC 
500047 Wnt16 ACTGTATGGTCGCCACTGC TGGTGCCGCTACTCAGTTC 
Oligonucleotides for ChIP   
Gene ID Gene Symbol Sense (5'->3') Antisense (5'->3') 
6352 CCL5 TGAGTTTGGACAAACCACAACTAGAATG CGCCTGGTATCTTTATAGTCCTGTCG 
2597 GAPDH GTTTCATCCAAGCGTGTAAGG GTCTTGAGGCCTGAGCTACG 
3627 IP10/CXCL10 GCATTATAGTTAGAATGGATTGCAACC CTCAGAAAACGTGGGCTAGTGTG 
4843 NOS2 CTCTGTGCCAATAGCCTTCC CCTCAGTTTTCGACTCGC 
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Supplementary table 2: Hedgehog pathway genes. 
 
Supplementary table 2 summarizes the results of the microarray, as well as of the qPCR for 
genes associated with the hedgehog pathway. Genes were assigned in accordance with the 
KEGG database. Genes are represented by gene-IDs and official gene-symbols. Micorarray 
and qPCR results are displayed per time point and treatment. Numbers denote fold changes, 
compared to the normal control kidneys. N.s.: non-significant regulation measured by qPCR. 
The last column displays if a gene is annotated to the array or not.  
Supplementary data 
 117
Supplementary table 3: Wnt canonical pathway genes. 
 
Supplementary table 3 summarizes the results of the microarray, as well as of the qPCR for 
genes associated with the WNT canonical pathway. Genes were assigned in accordance 
with the KEGG database. Genes are represented by gene-IDs and official gene-symbols. 
Micorarray and qPCR results are displayed per time point and treatment. Numbers denote 
fold changes, compared to the normal control kidneys. N.s.: non-significant regulation 
measured by qPCR. The last column displays if a gene is annotated to the array or not.  
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Supplementary table 4: Wnt - Ca+ pathway genes. 
 
Supplementary table 2 summarizes the results of the microarray, as well as of the qPCR for 
genes associated with the WNT-Ca2+ pathway. Genes were assigned in accordance with 
the KEGG database. Genes are represented by gene-IDs and official gene-symbols. 
Micorarray and qPCR results are displayed per time point and treatment. Numbers denote 
fold changes, compared to the normal control kidneys. N.s.: non-significant regulation 
measured by qPCR. The last column displays if a gene is annotated to the array or not.  
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Supplementary figure 1: HH pathway Placebo vs RA, day 7. Part 1 
 
 
Microarray analysis of the hedgehog pathway. The scheme is a modified version of the 
pathway displayed on the KEGG database for rat . A white box marks a gene not annotated 
to the microarray. Triangles indicate the up or downregulation of genes in comparison to the 
control kidney. Red triangles indicate upregulation and green triangles indicate down-
regulation. The numbers displayed are ChipInspector generated fold changes (native scale, 
not log transformed). 
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Supplementary figure 1: HH pathway Placebo vs RA, day 14. Part 2 
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Supplementary figure 2: WNT canonical pathway Placebo vs RA, day 7. Part 1 
 
 
 
Microarray analysis of the Wnt canonical pathway. The scheme is a modified version of 
the pathway displayed on the KEGG database for rat . A white box marks a gene not 
annotated to the microarray. Triangles indicate the up or downregulation of genes in 
comparison to the control kidney. Red triangles indicate upregulation and green triangles 
indicate downregulation. The numbers displayed are ChipInspector generated fold changes 
(native scale, not log transformed). 
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Supplementary figure 3: WNT-Ca2+ pathway Placebo vs RA, day 7. Part  1 
 
 
Microarray analysis of the Wnt-Ca2+ pathway. The scheme is a modified version of the 
pathway displayed on the KEGG database for rat . A white box marks a gene not annotated 
to the microarray. Triangles indicate the up or downregulation of genes in comparison to the 
control kidney. Red triangles indicate upregulation and green triangles indicate 
downregulation. The numbers displayed are ChipInspector generated fold changes (native 
scale, not log transformed).  
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Supplementary figure 3: WNT-Ca2+ pathway Placebo vs RA, day 14. Part 2 
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Supplementary figure 2: WNT canonical pathway Placebo vs RA, day 14. Part 2 
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Kumar D, Hosse J, von Toerne C, Noessner E, Nelson PJ. JNK MAPK pathway regulates 
constitutive transcription of CCL5 by human NK cells through SP1. J Immunol. 2009 Jan 
15;182(2):1011–20. 
 
Christine von Toerne, Claudia Schmidt, Judith Adams, Eva Kiss, Jens Bedke, Stefan 
Porubsky, Norbert Gretz, Maja T. Lindenmeyer, Clemens D. Cohen, Hermann–Josef Gröne 
and Peter J. Nelson WNT Pathway Regulation in Chronic Renal Allograft Dysfunction 
American Journal of Transplantation, in press 
Publications in preparation 
von Toerne, Christine, Schmidt, Claudia, Kiss, Eva, Loewe, Robert, Gröne, H.-J., Nelson, 
Peter RA treatment influences Wnt and Hedghog regulatory in a model of chronic 
allograft damage(in writing) 
 
von Toerne, Christine, Diedrichs-Möhring, Maria, Sieg, Cornelia, Nelson, Peter J., Wildner, 
Gerhild Differential gene expression in autoantigen-specific T cell lines causing 
monophasic or recurrent EAU in Lewis rats (in writing) 
 
Talks 
Kongress für Nephrologie (38. Kongress der Gesellschaft für Nephrologie-GfN), 22.-25. 
September, C. von Törne et al. Einfluss von 13-cis Retinsäure auf 
Signaltransduktionswege in fibrotischen und entzündlichen Vorgängen bei renalen 
allogenen Transplantationen 
Poster presentations 
Cold Spring Harbor Laboratory Meeting: Epithelial-Mesenchymal Transition, March 17-20, 
2008, Christine von Toerne et al. Influence of WNT and TGFβ pathway activation on 
EMT in fibrosis and inflammation 
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Supplementary figure 4: Chromatin immunoprecipitation results 
 
This figure displays the original 2% agarose gels of the ChIP experiment discussed. Due to 
problems with the colour assignment after scanning the original photographs the colour 
information has been recalculated for black and white values only. PCR has been performed 
using (A) CCL5, (B) CXCL10/IP10, (C) NOS2 primer pairs as described in 4.4.5. Signals 
could be detected in all input samples, the actual samples of the TNFA treated group ((A) 
lane 8, (B) lane 9, (C) lane 3) and the no-antibody controls of the CCL5 ((A) lane 9) and the 
CXCL10/IP10 ((B) lane 4) PCRs.  
Abbreviations: M: 1kb marker, nAB: no-antibody control, Iso/Iso control: isotype control, 
S/Samples: ChIP sample after precipitation with the NCOR antibody, -: unstimulated sample, 
T: TNFA stimulated sample, T/R: TNFA plus RA stimulated sample, Mock: mock control for 
buffers, containing no chromatin sample, Input: input control 1% of total DNA. .
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